1
|
Villani V, Tanzilli A, Telera S, Zucchella C, Carapella CM, Terrenato I, Boccaletti R, Pace A. P01.161 Neurocognitive evaluation in elderly Glioma patients. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- V Villani
- National Cancer Institute Regina Elena, Rome, Italy
| | - A Tanzilli
- National Cancer Institute Regina Elena, Rome, Italy
| | - S Telera
- National Cancer Institute Regina Elena, Rome, Italy
| | | | | | - I Terrenato
- National Cancer Institute Regina Elena, Rome, Italy
| | - R Boccaletti
- National Cancer Institute Regina Elena, Rome, Italy
| | - A Pace
- National Cancer Institute Regina Elena, Rome, Italy
| |
Collapse
|
2
|
Villani V, Chiaravalloti A, Vidiri A, Telera S, Carapella CM, Pace A. P09.11 Role of PET [18F]-FDOPA in the evaluation of low grade gliomas. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Villani V, Fabi A, Lombardi G, Bellu L, Zagonel V, Carapella CM, Sperduti I, Vidiri A, Pace A. P08.65 Evaluation of Clinical Benefit in patients treated with Bevacizumab. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Oppido PA, Carapella CM. P08.64 5-ALA fluorescence-guided surgical resection of glioblastoma in the elderly. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Pace A, Villani V, Benincasa D, Di Pasquale A, Carapella CM, Pompili A. P18.07 * PALLIATIVE SEDATION FOR BRAIN TUMOR PATIENTS AT THE END OF LIFE. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Villani V, Fabi A, Terrenato I, Telera S, Marucci L, Carosi M, Vidiri A, Carapella CM, Pace A. P17.93 * THIRD LINE CHEMOTHERAPY IN HIGH GRADE GLIOMAS: THERE IS A BENEFIT? Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Pace A, Antenucci A, Mandoj C, Villani V, Carapella CM, Fabi A, Conti L. P17.64 * ANGIOGENIC AND PROCOAGULANT FACTORS IN PLASMA OF BRAIN TUMOUR PATIENTS TREATED WITH BEVACIZUMAB. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Oppido PA, Carapella CM, Pompili A, Vidiri A, Pace A, Villani V. P12.10 * 5-ALA GUIDED REMOVAL AND COMBINED TREATMENT IN MALIGNANT GLIOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Pace A, Villani V, Vidiri A, Chiaravalloti A, Floris R, Schillaci O, Fabi A, Terrenato I, Piludu F, Carapella CM. P16.25 * THE ROLE OF PET F-FDOPA IN THE EVALUATION OF GLIOMAS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Maschio M, Dispenza S, Dinapoli L, Giannarelli D, Fabi A, Pompili A, Carapella CM, Vidiri A, Pace A, Cantelmi T. P18.06 * ZONISAMIDE AS ADD-ON ANTIEPILEPTIC DRUG IN PATIENTS WITH BRAIN TUMOR-RELATED EPILEPSY: PRELIMINARY DATA OF A PILOT STUDY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Vidiri A, Marzi S, Piludu F, Villani V, Antenucci A, Terrenato I, Fabi A, Pace A, Carapella CM. P16.06 * EARLY PERFUSION CHANGES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS TREATED WITH BEVACIZUMAB: PRELIMINARY EVALUATION BY THE PARAMETRIC RESPONSE MAP DERIVED FROM DYNAMIC CONTRAST-ENHANCED MRI. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Fabi A, Villani V, Pace A, Antonello V, Maschio M, Carapella CM, Carosi MA, Cognetti F, Marucci L, Terrenato I. P17.31 * LONG-TERM SURVIVAL OF GLIOBLASTOMA PATIENTS: WHICH CLINICAL AND MOLECULAR CORRELATION? Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Oppido PA, Cattani F, Carapella CM, Villani V. O5.09 * VENTRICULAR HIGH GRADE GLIOMA: NEUROENDOSCOPY AND ADJUVANT THERAPY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, de Groot J, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi JI, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M, Apok V, Mills S, Soh C, Karabatsou K, Arimappamagan A, Arya S, Majaid M, Somanna S, Santosh V, Schaff L, Armentano F, Harrison C, Lassman A, McKhann G, Iwamoto F, Armstrong T, Yuan Y, Liu D, Acquaye A, Vera-Bolanos E, Diefes K, Heathcock L, Cahill D, Gilbert M, Aldape K, Arrillaga-Romany I, Ruddy K, Greenberg S, Nayak L, Avgeropoulos N, Avgeropoulos G, Riggs G, Reilly C, Banerji N, Bruns P, Hoag M, Gilliland K, Trusheim J, Bekaert L, Borha A, Emery E, Busson A, Guillamo JS, Bell M, Harrison C, Armentano F, Lassman A, Connolly ES, Khandji A, Iwamoto F, Blakeley J, Ye X, Bergner A, Dombi E, Zalewski C, Follmer K, Halpin C, Fayad L, Jacobs M, Baldwin A, Langmead S, Whitcomb T, Jennings D, Widemann B, Plotkin S, Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, Revil C, Lutiger B, Carpentier AF, Milojkovic-Kerklaan B, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, van Linde M, Awada A, Schellens J, Brandsma D, Brenner A, Sun J, Floyd J, Hart C, Eng C, Fichtel L, Gruslova A, Lodi A, Tiziani S, Bridge CA, Baldock A, Kumthekar P, Dilfer P, Johnston SK, Jacobs J, Corwin D, Guyman L, Rockne R, Sonabend A, Cloney M, Canoll P, Swanson KR, Bromberg J, Schouten H, Schaafsma R, Baars J, Brandsma D, Lugtenburg P, van Montfort C, van den Bent M, Doorduijn J, Spalding A, LaRocca R, Haninger D, Saaraswat T, Coombs L, Rai S, Burton E, Burzynski G, Burzynski S, Janicki T, Marszalek A, Burzynski S, Janicki T, Burzynski G, Marszalek A, Cachia D, Smith T, Cardona AF, Mayor LC, Jimenez E, Hakim F, Yepes C, Bermudez S, Useche N, Asencio JL, Mejia JA, Vargas C, Otero JM, Carranza H, Ortiz LD, Cardona AF, Ortiz LD, Jimenez E, Hakim F, Yepes C, Useche N, Bermudez S, Asencio JL, Carranza H, Vargas C, Otero JM, Bartels C, Quintero A, Restrepo CE, Gomez S, Bernal-Vaca L, Lema M, Cardona AF, Ortiz LD, Useche N, Bermudez S, Jimenez E, Hakim F, Yepes C, Mejia JA, Bernal-Vaca L, Restrepo CE, Gomez S, Quintero A, Bartels C, Carranza H, Vargas C, Otero JM, Carlo M, Omuro A, Grommes C, Kris M, Nolan C, Pentsova E, Pietanza M, Kaley T, Carrabba G, Giammattei L, Draghi R, Conte V, Martinelli I, Caroli M, Bertani G, Locatelli M, Rampini P, Artoni A, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Locatelli M, Caroli M, Rampini P, Chamberlain M, Raizer J, Soffetti R, Ruda R, Brandsma D, Boogerd W, Taillibert S, Le Rhun E, Jaeckle K, van den Bent M, Wen P, Chamberlain M, Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Kerloeguen Y, Guijarro A, Cloughsey T, Choi JH, Hong YK, Conrad C, Yung WKA, deGroot J, Gilbert M, Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D, Costa R, Lycette J, Gancher S, Cullen J, Winer E, Hochberg F, Sachs G, Jeyapalan S, Dahiya S, Stevens G, Peereboom D, Ahluwalia M, Daras M, Hsu M, Kaley T, Panageas K, Curry R, Avila E, Fuente MDL, Omuro A, DeAngelis L, Desjardins A, Sampson J, Peters K, Ranjan T, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman H, Bigner D, Gromeier M, Prust M, Kalpathy-Cramer J, Poloskova P, Jafari-Khouzani K, Gerstner E, Dietrich J, Fabi A, Villani V, Vaccaro V, Vidiri A, Giannarelli D, Piludu F, Anelli V, Carapella C, Cognetti F, Pace A, Flowers A, Flowers A, Killory B, Furuse M, Miyatake SI, Kawabata S, Kuroiwa T, Garciarena P, Anderson MD, Hamilton J, Schellingerhout D, Fuller GN, Sawaya R, Gilbert MR, Gilbert M, Pugh S, Won M, Blumenthal D, Vogelbaum M, Aldape K, Colman H, Chakravarti A, Jeraj R, Dignam J, Armstrong T, Wefel J, Brown P, Jaeckle K, Schiff D, Brachman D, Werner-Wasik M, Tremont-Lukats I, Sulman E, Mehta M, Gill B, Yun J, Goldstein H, Malone H, Pisapia D, Sonabend AM, Mckhann GK, Sisti MB, Sims P, Canoll P, Bruce JN, Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M, Gore M, Hariharan S, Porta C, Bjarnason G, Bracarda S, Hawkins R, Oudard S, Zhang K, Fly K, Matczak E, Szczylik C, Grossman R, Ram Z, Hamza M, O'Brien B, Mandel J, DeGroot J, Han S, Molinaro A, Berger M, Prados M, Chang S, Clarke J, Butowski N, Hashimoto N, Chiba Y, Tsuboi A, Kinoshita M, Hirayama R, Kagawa N, Oka Y, Oji Y, Sugiyama H, Yoshimine T, Hawkins-Daarud A, Jackson PR, Swanson KR, Sarmiento JM, Ly D, Jutla J, Ortega A, Carico C, Dickinson H, Phuphanich S, Rudnick J, Patil C, Hu J, Iglseder S, Nowosielski M, Nevinny-Stickel M, Stockhammer G, Jain R, Poisson L, Scarpace L, Mikkelsen T, Kirby J, Freymann J, Hwang S, Gutman D, Jaffe C, Brat D, Flanders A, Janicki T, Burzynski S, Burzynski G, Marszalek A, Jiang C, Wang H, Jo J, Williams B, Smolkin M, Wintermark M, Shaffrey M, Schiff D, Juratli T, Soucek S, Kirsch M, Schackert G, Kakkar A, Kumar S, Bhagat U, Kumar A, Suri A, Singh M, Sharma M, Sarkar C, Suri V, Kaley T, Barani I, Chamberlain M, McDermott M, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Trojanec R, Hajduch M, Kneblova M, Ehrmann J, Kanner AA, Wong ET, Villano JL, Ram Z, Khatua S, Fuller G, Dasgupta S, Rytting M, Vats T, Zaky W, Khatua S, Sandberg D, Foresman L, Zaky W, Kieran M, Geoerger B, Casanova M, Chisholm J, Aerts I, Bouffet E, Brandes AA, Leary SES, Sullivan M, Bailey S, Cohen K, Mason W, Kalambakas S, Deshpande P, Tai F, Hurh E, McDonald TJ, Kieran M, Hargrave D, Wen PY, Goldman S, Amakye D, Patton M, Tai F, Moreno L, Kim CY, Kim T, Han JH, Kim YJ, Kim IA, Yun CH, Jung HW, Koekkoek JAF, Reijneveld JC, Dirven L, Postma TJ, Vos MJ, Heimans JJ, Taphoorn MJB, Koeppen S, Hense J, Kong XT, Davidson T, Lai A, Cloughesy T, Nghiemphu PL, Kong DS, Choi YL, Seol HJ, Lee JI, Nam DH, Kool M, Jones DTW, Jager N, Northcott PA, Pugh T, Hovestadt V, Markant S, Esparza LA, Bourdeaut F, Remke M, Taylor MD, Cho YJ, Pomeroy SL, Schuller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM, Krel R, Krutoshinskaya Y, Rosiello A, Seidman R, Kowalska A, Kudo T, Hata Y, Maehara T, Kumthekar P, Bridge C, Patel V, Rademaker A, Helenowski I, Mrugala M, Rockhill J, Swanson K, Grimm S, Raizer J, Meletath S, Bennett M, Nestor VA, Fink KL, Lee E, Reardon D, Schiff D, Drappatz J, Muzikansky A, Hammond S, Grimm S, Norden A, Beroukhim R, McCluskey C, Chi A, Batchelor T, Smith K, Gaffey S, Gerard M, Snodgras S, Raizer J, Wen P, Leeper H, Johnson D, Lima J, Porensky E, Cavaliere R, Lin A, Liu J, Evans J, Leuthardt E, Dacey R, Dowling J, Kim A, Zipfel G, Grubb R, Huang J, Robinson C, Simpson J, Linette G, Chicoine M, Tran D, Liubinas SV, D'Abaco GM, Moffat B, Gonzales M, Feleppa F, Nowell CJ, Gorelick A, Drummond KJ, Morokoff AP, O'Brien TJ, Kaye AH, Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R, Lupica K, Stevens G, Ly I, Hamilton S, Rostomily R, Rockhill J, Mrugala M, Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M, Burzynski S, Janicki T, Burzynski G, Marszalek A, Pachow D, Kliese N, Kirches E, Mawrin C, McNamara MG, Lwin Z, Jiang H, Chung C, Millar BA, Sahgal A, Laperriere N, Mason WP, Megyesi J, Salehi F, Merker V, Slusarz K, Muzikansky A, Francis S, Plotkin S, Mishima K, Adachi JI, Suzuki T, Uchida E, Yanagawa T, Watanabe Y, Fukuoka K, Yanagisawa T, Wakiya K, Fujimaki T, Nishikawa R, Moiyadi A, Kannan S, Sridhar E, Gupta T, Shetty P, Jalali R, Alshami J, Lecavalier-Barsoum M, Guiot MC, Tampieri D, Kavan P, Muanza T, Nagane M, Kobayashi K, Takayama N, Shiokawa Y, Nakamura H, Makino K, Hideo T, Kuroda JI, Shinojima N, Yano S, Kuratsu JI, Nambudiri N, Arrilaga I, Dunn I, Folkerth R, Chi S, Reardon D, Nayak L, Omuro A, DeAngelis L, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas J, Reimers HJ, Peereboom D, Rosenfeld S, Garst J, Ramnath N, Wing P, Zheng M, Urban P, Abrey L, Wen P, Nayak L, DeAngelis LM, Wen PY, Brandes AA, Soffietti R, Peereboom DM, Lin NU, Chamberlain M, Macdonald D, Galanis E, Perry J, Jaeckle K, Mehta M, Stupp R, van den Bent M, Reardon DA, Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P, Norden A, Schiff D, Ahluwalia M, Lesser G, Nayak L, Lee E, Muzikansky A, Dietrich J, Smith K, Gaffey S, McCluskey C, Ligon K, Reardon D, Wen P, Bush NAO, Kesari S, Scott B, Ohno M, Narita Y, Miyakita Y, Arita H, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Shibui S, Okamura T, Kaneko S, Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire JP, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, del Rio MS, Gonzalez-Aguilar A, Houllier C, Tanguy ML, Hoang-Xuan K, Omuro A, Abrey L, Raizer J, Paleologos N, Forsyth P, DeAngelis L, Kaley T, Louis D, Cairncross JG, Matasar M, Mehta J, Grimm S, Moskowitz C, Sauter C, Opinaldo P, Torcuator R, Ortiz LD, Cardona AF, Hakim F, Jimenez E, Yepes C, Useche N, Bermudez S, Mejia JA, Asencio JL, Carranza H, Vargas C, Otero JM, Lema M, Pace A, Villani V, Fabi A, Carapella CM, Patel A, Allen J, Dicker D, Sheehan J, El-Deiry W, Glantz M, Tsyvkin E, Rauschkolb P, Pentsova E, Lee M, Perez A, Norton J, Uschmann H, Chamczuck A, Khan M, Fratkin J, Rahman R, Hempfling K, Norden A, Reardon DA, Nayak L, Rinne M, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Wen P, Lee E, Ranjan T, Peters K, Vlahovic G, Friedman H, Desjardins A, Reveles I, Brenner A, Ruda R, Bello L, Castellano A, Bertero L, Bosa C, Trevisan E, Riva M, Donativi M, Falini A, Soffietti R, Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Nishikawa R, Dahr S, Hilton M, Garcia J, Cloughesy T, Sasaki H, Nishiyama Y, Yoshida K, Hirose Y, Schwartz M, Grimm S, Kumthekar P, Fralin S, Rice L, Drawz A, Helenowski I, Rademaker A, Raizer J, Schwartz K, Chang H, Nikolai M, Kurniali P, Olson K, Pernicone J, Sweeley C, Noel M, Sharma M, Gupta R, Suri V, Singh M, Sarkar C, Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T, Shih K, Chowdhary S, Rosenblatt P, Weir AB, Shepard G, Williams JT, Shastry M, Hainsworth JD, Singer S, Riely GJ, Kris MG, Grommes C, Sanders MWCB, Arik Y, Seute T, Robe PAJT, Leijten FSS, Snijders TJ, Sturla L, Culhane JJ, Donahue J, Jeyapalan S, Suchorska B, Jansen N, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Bartenstein P, Schnell O, Kreth FW, LaFougere C, Tonn JC, Taillandier L, Wittwer B, Blonski M, Faure G, De Carvalho M, Le Rhun E, Tanaka K, Sasayama T, Nishihara M, Mizukawa K, Kohmura E, Taylor S, Newell K, Graves L, Timmer M, Cramer C, Rohn G, Goldbrunner R, Turner S, Gergel T, Lacroix M, Toms S, Ueki K, Higuchi F, Sakamoto S, Kim P, Salgado MAV, Rueda AG, Urzaiz LL, Villanueva MG, Millan JMS, Cervantes ER, Pampliega RA, de Pedro MDA, Berrocal VR, Mena AC, van Zanten SV, Jansen M, van Vuurden D, Huisman M, Hoekstra O, van Dongen G, Kaspers GJ, Schlamann A, von Bueren AO, Hagel C, Kramm C, Kortmann RD, Muller K, Friedrich C, Muller K, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Gerber NU, Hau P, Kuehl J, Kortmann RD, von Bueren AO, Rutkowski S, von Bueren AO, Friedrich C, von Hoff K, Kwiecien R, Muller K, Pietsch T, Warmuth-Metz M, Kuehl J, Kortmann RD, Rutkowski S, Walker J, Tremont I, Armstrong T, Wang H, Jiang C, Wang H, Jiang C, Warren P, Robert S, Lahti A, White D, Reid M, Nabors L, Sontheimer H, Wen P, Yung A, Mellinghoff I, Lamborn K, Ramkissoon S, Cloughesy T, Rinne M, Omuro A, DeAngelis L, Gilbert M, Chi A, Batchelor T, Colman H, Chang S, Nayak L, Massacesi C, DiTomaso E, Prados M, Reardon D, Ligon K, Wong ET, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD, Elzinga G, Chung A, Wong ET, Wu W, Galanis E, Wen P, Das A, Fine H, Cloughesy T, Sargent D, Yoon WS, Yang SH, Chung DS, Jeun SS, Hong YK, Yust-Katz S, Milbourne A, Diane L, Gilbert M, Armstrong T, Zaky W, Weinberg J, Fuller G, Ketonen L, McAleer MF, Ahmed N, Khatua S, Zaky W, Olar A, Stewart J, Sandberg D, Foresman L, Ketonen L, Khatua S. NEURO/MEDICAL ONCOLOGY. Neuro Oncol 2013; 15:iii98-iii135. [PMCID: PMC3823897 DOI: 10.1093/neuonc/not182] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023] Open
|
15
|
Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS, Lin L, Amidei C, Lovely M, Arzbaecher J, Page M, Mogensen K, Lupica K, Maher ME, Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh S, Wendland MM, Brachman DG, Brown PD, Crocker IR, Robins HI, Lee RJ, Mehta M, Arvold N, Wang Y, Zigler C, Schrag D, Dominici F, Boele F, Douw L, de Groot M, van Thuijl H, Cleijne W, Heimans J, Taphoorn M, Reijneveld J, Klein M, Bunevicius A, Tamasauskas S, Tamasauskas A, Deltuva V, Bunevicius R, Cahill J, Lin L, Armstrong T, Acquaye A, Vera-Bolanos E, Gilbert M, Padhye N, Chan J, Clarke J, Lawton K, Rabbitt J, DeSilva A, Prados M, Rosen M, Cher L, Diamond E, Applebaum A, Corner G, DeRosa A, Breitbart W, DeAngelis L, Hoogendoorn P, Ikuta S, Muragaki Y, Maruyama T, Nitta M, Tamura M, Okamoto S, Iseki H, Okada Y, Lacouture M, Davis ME, Elzinga G, Butowski N, Tran D, Villano J, Wong E, Legge D, Cher L, Legge D, Cher L, Mills K, Lin L, Acquaye A, Vera-Bolanos E, Gilbert M, Armstrong T, Lovely M, Sullivan D, Mueller S, Fullerton H, Stratton K, Leisenring W, Armstrong G, Weathers R, Stovall M, Goldsby R, Sklar C, Robison L, Krull K, Pace A, Villani V, Focarelli S, Benincasa D, Benincasa A, Carapella CM, Pompili A, Peiffer AM, Burke A, Leyer CM, Shing E, Kearns WT, Hinson WH, Case D, Rapp SR, Shaw EG, Chan MD, Porensky E, Cavaliere R, Newton H, Shilds A, Burgess S, Ravelo A, Taylor F, Mazar I, Abrey L, Rooney A, Graham C, McKenzie H, Fraser M, MacKinnon M, McNamara S, Rampling R, Carson A, Grant R, Rooney A, Heimans L, Woltz S, Kerrigan S, McNamara S, Grant R, Seibl-Leven M, Wittenstein K, Rohn G, Goldbrunner R, Timmer M, Kennedy J, Sherman W, Sen-Gupta I, Garic I, Macken M, Gerard E, Raizer J, Schuele S, Grontoft M, Stragliotto G, Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason W, Saran F, Nishikawa R, Ravelo A, Hilton M, Chinot OL, Trad W, Simpson T, Wright K, Tran T, Choong C, Barton M, Hovey E, Robinson K, Koh ES, Vera-Bolanos E, Acquaye AA, Brown PD, Chung C, Gilbert MR, Vardy J, Armstrong TS, Walbert T, Mendoza T, Vera-Bolanos E, Gilbert M, Acquaye A, Armstrong T, Walbert T, Glantz M, Schultz L, Puduvalli VK, Oudenhoven M, Farin C, Hoffman R, Armstrong T, Ewend M, Wu J. SYMPTOM MANAGEMENT/QUALITY OF LIFE. Neuro Oncol 2013; 15:iii226-iii234. [PMCID: PMC3823907 DOI: 10.1093/neuonc/not192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2024] Open
|
16
|
Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M, Perin A, Verginelli F, Dali R, Hei Man Fung K, Lo R, Longatti P, Guiot M, Del Maestro RF, Rossi S, Di Porzio U, Stechishin O, Weiss S, Stifani S, Sanzey M, Golebiewska A, Stieber D, Nazarov P, Muller A, Vallar L, Niclou SP, Lawler SE, Chiocca E, Williams SP, Wanka C, Steinbach JP, Rieger J, Lavon I, Zrihan D, Refael M, Siegal T, Sminia P, Van Nifterik KA, Van den Berg J, Lafleur VM, Stalpers LJA, Slotman BJ, Di stefano A, Enciso-Mora V, Marie Y, Desestret V, Labussiere M, Idbaih A, Hoang-Xuan K, Delattre J, Houlston R, Sanson M, Woehrer A, Slavc I, Stefanits H, Waldhoer T, Heinzl H, Zielonke N, Czech T, Hainfellner JA, Haberler C, Zouaoui S, Darlix A, Virion J, Rigau V, Mathieu-Daude H, Bauchet F, Figarella-Branger D, Duffau H, Taillandier L, Bauchet L, Naydenov E, Popov R, Tanova R, Minkin K, De Vleeschouwer S, Van Gool S, Cavaletti G, Wilbers J, Hoebers F, Boogerd W, van Werkhoven E, Nowee M, Hart G, van Dijk E, Kappelle A, Dorresteijn L, Furuse M, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Miyatake S, Boele FW, Heimans JJ, Aaronson NK, Peereboom DM, Sloan AE, Supko JG, Ye X, Rich JN, Prados MD, Ahluwalia M, Grossman SA, Spiegl-Kreinecker S, Loetsch D, Taphoorn MJB, Wild M, Ghanim B, Pirker C, Pichler J, Serge W, Lenz S, Wurm G, Berger W, Tamiya T, Miyake K, Postma TJ, Okada M, Kawai N, Grossi I, Rigakos G, Lampropoulos S, Stavridi F, Tsoulos N, Nasioulas G, Papadopoulou E, Razis E, Reijneveld JC, Schroeteler J, Klosterkemper Y, Schwake M, Stummer W, Ewelt C, Field KM, Rosenthal MA, Wheeler H, Cher L, Hovey E, Klein M, Nowak AK, Brown C, Livingstone A, Sawkins K, Simes J, Linsenmann T, Jawork A, Hagemann C, Kessler AF, Berg F, Habets EJJ, Lohr M, Ernestus RI, Vince GH, Rodriguez FJ, Heaphy CM, Nguyen DN, de Wilde RF, Orr B, Raabe E, Eberhart CG, Taphoorn MJB, Meeker AK, Klein SP, Van Calenbergh F, van Loon J, Menten J, Clement P, De Vleeschouwer S, Goffin J, Lonardi F, Gioga G, Nederend S, Bonometti M, Ferigo L, Buonocore F, Campostrini F, Golebiewska A, Bougnaud S, Stieber D, Brons N, Vallar L, Hertel F, Klein M, Bjerkvig R, Niclou S, Strik HM, Carl B, Kallenberg K, Moiyadi AV, Gupta T, Shetty P, Nair V, Jalali R, Delgadillo D, Compter I, de Kunder SL, Houben RMA, Jager JJ, Bosmans G, Anten MHME, Baumert BG, Duerinck J, Du Four S, Van Binst A, Xuan KH, Everaert H, Michotte A, D'haens J, Neyns B, Basmaci M, Hasturk AE, de Kunder SL, Compter I, Schijns OEMG, ter Laak-Poort MP, Bottomley A, Anten MHME, Jansen RLH, Baumert BG, Happold C, Roth P, Wick W, Schmidt N, Florea A, Reifenberger G, Weller M, Van den Bent MJ, Ho C, Leugner D, Easaw J, Lim G, Rosenberg T, Thomassen M, Jensen S, Larsen M, Sorensen K, Hermansen S, Reijneveld JC, Kruse T, Kristensen B, Pichler J, Hollmuller I, Ghanim B, Spiegl-Kreinecker S, Ursu R, Ferrari D, Bailon O, Augier A, Minaya Flores P, Dubessy A, Banissi C, Belin C, Levy C, Carpentier AF, Boudouresque F, Delphino C, Metellus P, Pirisi V, Figarella-Branger D, Chinot O, Ouafik L, Berthois Y, Nakamura H, Makino K, Hide T, Yano S, Kuratsu J, Stevens GHJ, Ahluwalia M, Hashemi N, Berbis J, Peereboom D, Barnett GH, Wibom C, Ghasimi S, Van Loo P, Brannstrom T, Trygg J, Henriksson R, Bergenheim T, Andersson U, Auquier P, Ryden P, Melin B, Ackerl MS, Flechl B, Dieckmann K, Preusser M, Widhalm G, Sax C, Marosi C, Seliger C, Kumthekar PU, Leukel P, Jachnik B, Bogdahn U, Vollmann A, Hau P, Chung SA, Luk PP, Shen H, Decollogne S, Day BW, Grimm SA, Stringer BW, Hogg PJ, Dilda PJ, McDonald KL, Cernea DR, Pruteanu P, Todor N, Florian S, Bogdan V, Cercea C, Chandler J, Leibetseder A, Ackerl M, Flechl B, Sax C, Widhalm G, Dieckmann K, Preusser M, Marosi C, Torres-Martin M, Pena-Granero C, Helenowski IB, Isla A, Pinto GR, Custodio AC, Melendez B, Castresana JS, Rey JA, Banissi C, Maubant S, Rancic M, Carpentier AF, Marymont M, Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Kaneva R, Poptodorov G, Mitev V, Gabrovsky N, Rademaker A, Piccirillo SGM, Spiteri I, Sottoriva A, Marko N, Tavare' S, Collins P, Watts C, Fedrigo CA, Da Rocha AB, Stalpers LJA, Wagner L, Baumert BG, Slotman B, Peters GJ, Sminia P, Fernandez M, Gawrisch VJ, Ruttgers M, Jachnik B, Proescholdt M, Bogdahn U, Stell B, Vollmann-Zwerenz A, Hau P, Trevisan E, Magistrello M, Bertero L, Bosa C, Greco Crasto S, Garbossa D, Lolli I, Ruda R, Raizer J, Soffietti R, Ichikawa T, Kurozumi K, Onishi M, Ishida J, Shimazu Y, Fujii K, Inoue S, Chiocca EA, Kaur B, Kumthekar PU, Date I, Dictus C, Friauf S, Valous NA, Muerle B, Unterberg AW, Herold-Mende CC, Caroli M, Di Dristofori A, Lucarella F, Grimm S, Menghetti C, Lanfranchi G, Gaini SM, Duerinck J, Clement P, Bouttens F, Neyns B, D'Hondt L, Gennigens C, Staelens Y, Jacobs DI, Joosens E, Van Fraeyenhove F, Rogiers A, Darlix A, Baumann C, Lorgis V, Blonski M, Chauffert B, Zouaoui S, Beauchesne P, Stell BV, Taillandier L, Vaccaro V, Pace A, Vidiri A, Vari S, Telera S, Giannarelli D, Russillo M, Anelli V, Carapella CM, Rademaker A, Fabi A, Florian SI, Soritau O, Neagoe I, Abrudan C, Tomuleasa C, Cernea D, Petrescu M, Baritchii A, Florian SI, Chandler J, Abrudan C, Baritchii A, Fornara O, Mirza S, Khan Z, Odeberg J, Stragliotto G, Butler L, Soderberg-Naucler C, Soderberg Naucler C, Marymont MH, Stragliotto G, Peredo I, Rahbar A, Lilja A, Taher C, Orrego A, Wolmer Solberg N, Brandes AA, Depenni R, Marcello N, Helenowski IB, Valentini A, Faedi M, Urbini B, Crisi G, Franceschi E, Poggi R, Baruzzi A, Berghauser Pont LME, Kloezeman JJ, French PJ, Wagner L, Dirven CMF, Lamfers MLM, Leenstra SL, Stragliotto G, Bartek J, Hylin S, Peredo I, Rahbar A, Soderberg Naucler C, Dahlrot RH, Raizer JJ, Kristensen BW, Hjelmborg JVB, Herrstedt J, Hansen S, Nittby HC, Persson BRR, Ceberg C, Widegren B, Salford LG, Poulsen HS, Claudel G, Grunnet K, Michaelsen SR, Broholm H, Christensen IJ, Tinchon A, Oberndorfer S, Marosi C, Ruda R, Sax C, Calabek B, Muller C, Grisold W, Bouwens T, Trouw L, Heijsman D, Kremer A, van der Spek P, Dirven C, Lamfers M, Al-Khawaja H, Pollanz S, Colmar K, Tinchon A, Calabek B, Oberndorfer S, Pohnl R, Grisold W, Hong Y, Ko K, Lee E, De Groot M, Choenni EP, Garat E, Sizoo EM, Uitdehaag B, Buter J, Van Linde ME, Postma TJ, Taphoorn MJB, Heimans JJ, Reijneveld JC, Bertero L, Bosa C, Beauchesne P, Trevisan E, Tarenzi L, Garbossa D, Mantovani C, Soffietti R, Ruda R, Lotsch D, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Hassani K, Petznek H, Grusch M, Berger W, Kaloshi G, Spahiu O, Djamandi P, Djamandi P, Ruka M, Haxhihyseni E, Bushati T, Bethune B, Petrela M, Tabatabai G, Felsberg J, Sabel M, Hofer S, Westphal M, Weller M, Reifenberger G, Wertz M, Padovani L, Nguyen-Thi P, Bequet-Boucard C, Barrie M, Matta M, Muracciole X, Chinot O, Timmer M, Rohn G, Goldbrunner R, Thon N, Kreth F, Di Patrizio P, Simon M, Westphal M, Schackert G, Nikkhah G, Tatagiba M, Hentschel B, Weller M, Tonn J, Smrdel U, Fack F, Taillandier L, Zheng L, Frezza C, Keunen O, Kalna G, Nazarov P, Gottlieb E, Niclou SP, Bjerkvig R, Radic J, Murgic J, Sizoo EM, Maric Brozic J, Jazvic M, Soldic Z, Bolanca A, Raizer J, Grimm S, Levy R, Muro K, Rosenow J, Chandler J, Taphoorn MJB, Bredel M, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Cechakova E, Trojanec R, Kneblova M, Hajduch M, Ehrmann J, Uitdehaag B, Naskhletashvili DR, Gorbounova V, Bychkov M, Bekyashev A, Karakhan V, Aloshin V, Fu R, Moskvina E, Gaziel TB, Poulsen HS, Heimans JJ, Muhic A, Rahbar A, Peredo I, Wolmer Solberg N, Taher C, Dzabic M, Xu X, Skarman P, Tammik C, Stragliotto G, Deliens L, Soderberg-Naucler C, Ahluwalia MS, hashemi-Sadraei N, Barnett GH, Fabbro M, Laigre M, Langlois C, Castan F, Bauchet L, Duffau H, Reijneveld JC, Bonafe A, Spoor JKH, Khorami K, Kloezeman J, Balvers R, Dirven C, Lamfers M, Leenstra S, Spoor JKH, van der Kaaij M, Pasman HW, Kloezeman J, Geurtjens M, Dirven C, Lamfers M, Leenstra S, Trister AD, Neal ML, Cloke T, Baldock AL, Ahn S, Rampling RP, Mrugala MM, Rockhill JK, Rockne R, Swanson KR, Swanson KR, Rockne R, Hawkins-Daarud A, Corwin D, Neal ML, Rockhill JK, James A, Mrugala MM, Rostomily R, Alvord EC, D'Alessandro G, Catalano M, Cipriani R, Chece G, Limatola C, Graham K, Williamson A, Mulholland P, Lamb C, James A, Clark B, Chalmers A, de Kunder SL, Postma AA, Huysentruyt CJR, Dings J, ter Laak-Poort MP, Seystahl K, Peoples S, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A, Janz C, Buhl RM, Jiang T, Darlix A, Al-Salihi O, Virion J, Zouaoui S, Rigau V, Tretarre B, Mandonnet E, Pinelli C, Duffau H, Taillandier L, Bauchet L, Ng H, Twelves C, Yang L, Pang JCS, Roelcke U, Nowosielski M, Bertero L, Crippa F, Hofer S, Bruehlmeier M, Remonda L, Soffietti R, Halford S, Wyss M, Reyes-Botero G, Fiorelli M, Mokhtari K, Delattre J, Laigle-Donadey F, Amelio D, Lorentini S, Giri MG, Meliado G, McGuigan L, Fellin F, Gargano G, Ricciardi GK, Pioli F, Schwarz M, Amichetti M, Ribba B, Kaloshi G, Peyre M, Ricard D, Ritchie J, Tod M, Cartalat-Carel S, Delattre J, Honnorat J, Grenier E, Ducray F, Bastin F, Pirotte B, Bouquey D, Roger T, Sing-Jasuja H, Riva M, Raneri F, Pessina F, Casarotti A, Comi A, Fava E, Papagno C, Bello L, Blonski M, Pallud J, Schumacher T, Goze C, Mandonnet E, Beauchesne P, Baron M, Fontaine D, Darlix A, Duffau H, Taillandier L, Sinclair G, Hylin S, Sahm F, Nordstrom L, Stragliotto G, Mucha-Malecka A, Glinski B, Malecki K, Ahluwalia MS, Robles Irizarry L, Hashemi Sadraei N, Stevens G, Barnett GH, von Deimling A, Mucha-Malecka A, Glinski B, Malecki K, Jarosz M, Dymek P, Chrostowska A, Hetnal M, Miwa T, Oi S, Nonaka Y, Wick W, Sasaki H, Adachi J, Suzuki T, Yanagisawa T, Mishima K, Fukuoka K, Koga T, Matsutani M, Nishikawa R, Burger MC, Platten M, Brucker DP, Baumgarten P, Ronellenfitsch MW, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Mittelbronn M, Steinbach JP, Walker DA, Ardon H, Collier J, Kennedy C, Grundy R, Wilne S, Lakhanpaul M, Baker M, Trusler J, Linsell S, Dudley J, Kieffer V, Ewelt C, Dellatolas G, Chevignard M, Puget S, Dhermain F, Grill J, Dufour C, Messina R, Zambuto M, Calace A, De Tommasi A, Gunes D, Malova JV, Peyrl A, Sauermann R, Chocholous M, Azizi AA, Prucker C, Jaeger W, Hoeferl M, Slavc I, Pollo B, Wolfer J, Maderna E, Vuono R, Farinotti M, Massimino M, Finocchiaro G, Valentini L, Aurtenetxe O, Urberuaga A, Lopez J, Gaafar A, De Vleeschouwer S, Navajas A, Perez Bovet J, Kusak M, Martinez Moreno N, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Yachi K, Kurihara J, Fukushima T, Stummer W, Watanabe T, Yoshino A, Katayama Y, Nishimoto H, Ghasimi S, Haapasalo H, Eray M, Korhonen K, Brannstrom T, Hedman H, Wick W, Andersson U, Miyatake S, Kawabata S, Hiramatsu R, Hirota Y, Kuroiwa T, Ono K, Sugio H, Ito T, Ozaki Y, Meisner C, Sato K, Oikawa M, Daniel R, Tuleasca C, Negretti L, Magaddino V, Levivier M, Pfister C, Pfrommer H, Tatagiba MS, Hentschel B, Roser F, Linsler S, Reuss D, Urbschat S, Klotz M, Ketter R, Oertel J, Ketter R, Linsler S, Kramer D, Platten M, Driess C, Lerner C, Oertel J, Urbschat S, Williamson A, Smith S, Clark B, Chalmers A, James A, Saini SS, Sabel M, Hall G, Davis C, Jang W, Jung S, Jung T, Moon K, Kim I, Carrabba G, Conte V, Riva M, Koeppen S, Caroli M, Artoni A, Martinelli I, Gaini SM, Martinez Moreno NE, Kusak ME, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Megyesi JF, Ketter R, Macdonald D, Chaudhary N, Weber DC, Li J, Miller R, Villa S, Anacak Y, Poortmans P, Baumert B, Pica A, Simon M, Ozyigit G, Preusser M, Torres-Martin M, Lassaletta L, Pena-Granero C, de Campos JM, Gutierrez M, Castresana JS, Rey JA, Suki D, Reifenberger G, Sivaganean A, Rao G, Rhines LD, Caffo M, Barresi V, Cacciola F, Giugno A, Passalacqua M, Alafaci C, Caruso G, Weller M, Tomasello F, Widhalm G, Kiesel B, Novak K, Wohrer A, Matula C, Prayer D, Marosi C, Preusser M, Knosp E, Gallego Perez-Larraya J, Wolfsberger S, De Campos JM, Kusak ME, Aguirre DT, Ordonez C, Fortes J, Chamberlain MC, Ellithy MAM, Ghali RR, Abdelhakim KN, Sampron N, Abdelmonem A, Elwakil LM, Heesters MAAM, van der Weide HL, Bolt RA, Enting RH, Glaudemans AWMJ, Bijl HP, van Dijk JMC, Langendijk JA, Matheu A, Chmielowska E, Lewandowska K, Studzinski M, Olejniczak M, Kwiatkowski M, Subira D, Illan J, Serrano C, Simo M, Pardo J, Ayuso A, Martinez-Garcia M, Gil-Bazo I, Sepulveda JM, Hinojo C, Bruna J, Chmielowska E, Krause A, Swiezynski M, Lewandowska K, Olejniczak M, Paris S, Chung C, Menard C, Stevens C, Laperriere N, Millar B, Bernstein M, Zadeh G, Mason W, Brade A, Kim J, Tejada-Solis S, Pardo J, Bruna J, Gomez L, Subira D, Fernandez A, Serrano C, Gonzalez F, Velasco R, Gil M, Perez-Carrion R, Diez-Valle R, Levivier M, Magaddino V, Negretti L, Tuleasca C, Moeckli R, Auslands K, Liepa Z, Apskalne D, Ozols R, Ogino A, Lopez de Munain A, Hirai T, Fukushima T, Serizawa T, Yachi K, Ohta T, Watanabe T, Yoshino A, Hirayama T, Katayama Y, Slavc I, Manterola L, Chocholous M, Czech T, Peyrl A, Dorfer C, Prucker C, Haberler C, Woehrer A, Azizi A, Antoni D, Clavier J, Alonso MM, Noel G, Antoni D, Clavier J, Noel G, Pardo J, Cuadrado ML, Fernandez C, Broemme JO, Schucht P, Beck J, Weiler M, Abu-Isa J, Kottke R, Malthaner M, Schmidthalter D, Aebersold DM, Pica A, Carpentier A, Peignaux K, Bourgeois H, Fauchon F, Blaes J, Prevost J, Azria D, Toulemonde A, Lortholary A, Bonneterre J, Hennequin C, Du Four S, Wilgenhof S, Neyns B, Lam T, Sahm F, Wong F, Sze W, Tung S, Calabek B, Pollanz S, Surbock B, DeSantis M, Pohnl R, Ammerer H, Sherif C, Pusch S, Grisold W, Hanssens P, Beute G, Karlsson B, Naskhletashvili DR, Gorbounova V, Bychkov M, Bekyashev A, Karakhan V, Aloshin V, Jugold M, Moskvina E, Rudnicka H, Niwinska A, Murawska M, Save A, Baehring JM, Ghali RR, Basiuony ME, Elleithy MA, Martinez-Garcia M, Kempf T, Momprade E, Alameda F, Capellades J, Ruiz I, Vivanco RM, Manero RM, Foro P, Conesa G, Albanell J, Di Stefano A, Weller M, Berzero G, Vitali P, Bastianello S, Giometto B, Salmaggi A, Marchioni E, Velasco R, Simo M, Santos C, Gil M, Platten M, Salazar R, Galan M, Palmero R, Ale A, Bruna J, Lee DZJ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, Wick W, Yevtushenko S, Goncharova Y, Filimonov D, Symonian V, Viaccoz A, Karantoni E, Ducray F, Picard G, Cavillon G, Rogemond V, McDonald KL, Antoine J, Delattre J, Honnorat J, Koekkoek JAF, Sizoo EM, Postma TJ, Heimans JJ, Pasman RW, Deliens L, Taphoorn MJB, Rapkins R, Reijneveld JC, Muller C, Claudel G, Garat E, Beauchesne P, Hassani K, Labrude M, Taillandier L, Logan J, Hurwitz V, Zhau L, Bhangoo R, Ashkan K, Brazil L, Beaney R, Thier K, Calabek B, Tinchon A, Grisold W, Oberndorfer S, Kallio M, Hitchins M, Kaipio M, Baraniskin A, Kuhnhenn J, Schlegel U, Schmiegel W, hahn S, Schroers R, Mrugala MM, Crew LK, Mishima K, Agnihotri S, Suzuki T, Adachi J, Koga T, Fukuoka K, Yanagisawa T, Fujimaki T, Nishikawa R, Gonzalez-Aguilar A, Boisselier B, Polivka M, Gajadhar A, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Vital A, Mokhtari K, Hoang-Xuan K, Sommer B, Grummich P, Hamer HM, Gorlia T, Blumcke I, Coras R, Buchfelder M, Roessler K, Rozumenko VD, Rozumenko AV, Brell M, Roldan P, Gonzalez E, Ibanez J, Margison G, Ibanez J, Brell M, Tomas M, Roldan P, Guibelalde M, Tavera A, Salinas J, Van Geemen K, Klein M, Zwinderman AH, Aldape K, Hillebrand A, Stam CJ, Vandertop WP, De Witt Hamer PC, Senft C, Gessler F, Mittelbronn M, Dutzmann S, Franz K, Hattingen E, Hawkins C, Seifert V, Ngoga DG, Tennant D, Williams A, Cruickshank G, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Hegi M, Conte V, Caroli M, Gaini SM, Oppido P, Carapella C, Pompili A, Vidiri A, Pace A, Shinoda J, Miwa K, Guha A, Yonezawa S, Aki T, Asano Y, Ito T, Yokoyama K, Yamada M, Yamada J, Ceberg C, Jonsson B, Prezado Y, Simo M, Nittby H, Grafstrom G, Stromblad S, Elleaume H, Baldetorp B, Salford LG, Strand S, Hundsberger T, Brugge D, Weder P, Macia M, Weber J, Plasswilm L, Lopci E, Clerici E, Catalano M, Rodari M, Morenghi E, Mancosu P, Navarria P, Scorsetti M, Plans G, Chiti A, Fernandez M, Setua S, Watts C, Welland M, Martinez Moreno NE, Kusak ME, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Majos C, Narayan RS, Renwarin L, van den Berg J, Franken NAP, Stalpers LJA, Baumert BG, Sminia P, Mucha-Malecka A, Sladowska A, Malecki K, Gil M, Glinski B, Kisielewicz K, Torabi Nami M, Hejazi Farahmand S, Mohammadzadeh F, Shao C, Wu M, Xia Y, Chen F, Chen Z, Izquierdo C, Miyatake S, Yoritsune E, Furuse M, Miyata T, Nonoguchi N, Kawabata S, Kuroiwa T, Kuwabara H, Masunaga S, Ono K, Velasco R, Ros T, Horvat Sprah M, Popovic M, Jezersek Novakovic B, Kerrigan SJ, Erridge S, Whittle I, Grant R, Verissimo CS, Molenaar JJ, Bruna J, Meerman J, Puigvert JC, Pont C, Danen EHJ, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E, Marques J, Costa I, Yanagisawa T, Passos J, Azevedo A, Salgado D, Teixeira G, Ferreira I, Guimaraes A, Miranda N, Abecasis M, Bosa C, Magistrello M, Suzuki K, Trevisan E, Morra I, Fiano V, Dealis C, Ruda R, Soffietti R, Mackinnon M, Williamson A, Lamb C, Chalmers A, Fukuoka K, Clark B, James A, Fernandez M, Blanchette M, Tremblay L, Lepage M, Fortin D, Matos Nunes B, Bujor L, Vasconcelos A, Kohga T, Amado A, Monteiro Grillo I, Muggeri AD, Calabrese B, Cerrato S, Cervio A, Diez B, Moser W, Tinchon A, Calabek B, Adachi J, Hitzenberger P, Grisold W, Oberndorfer S, Kusak ME, De Campos JM, Martinez Moreno NE, Gutierrez Sarraga J, Rey Portoles G, Martinez Alvarez R, Kubben PL, MIshima K, De Campos JM, Vinas D, Kusak ME, Lo Presti A, Montoya J, Matsutani M, Fujimaki T, Nisikawa R, Kuhnhenn J, Pels H, Reiser M, Deckert M, Egerer G, Vogt-Schaden M, Schackert G, Kroschinsky F, Schmidt-Wolf IGH, Schlegel U, Schiff D, Taylor JW, Flanagan E, O'Neill BP, Siegal T, Omuro A, Baehring J, Gonzalez-Aguilar A, Chamberlain M, Nishikawa R, Zach L, Guez D, Grober Y, Last D, Daniels D, Hoffman C, Nissim O, Spiegelmann R, Cohen ZR, Mardor Y, Radbruch A, Kramp L, Wiestler B, Heiland S, Wick W, Bendszus M, Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E, Berghoff AS, Lassmann H, Hoftberger R, Preusser M, Mercurio-Smit S, Padovani L, Colin C, Andre N, Fernandez C, Figarella-Branger D, Ruda R, Bertero L, Trevisan E, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bomprezzi C, Soffietti R, Kunz M, Armbruster L, Thon N, Jansen N, Egensperger R, Eigenbrod S, Lutz J, Fougere la C, Tonn J, Kreth F, Berntsson S, Savitcheva I, Larsson E, Smits A, van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven M, Delattre JY, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WNM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang Xuan K, Weller M, Meisner C, Platten M, Simon M, Nikkhah G, Papsdorf K, Sabel M, Braun C, Reifenberger G, Wick W, Kerrigan SJ, Graham C, Stenning S, Thompson LC, Rooney A, Brada M, Grant R, Beauchesne PD, Faure G, Noel G, Schmitt T, Martin L, Jadaud E, Balvers R, Kloezeman JK, Kleijn A, Kremer A, French PJ, Dirven CMF, Leenstra S, Lamfers MLM, Bougnaud S, Golebiewska A, Oudin A, Brons NHC, Bjerkvig R, Niclou SP, Smith SJ, Ward JH, Wilson M, Rahman C, Rose F, Peet A, Macarthur DC, Grundy RG, Rahman R, Cuppini L, Calleri A, Bruzzone M, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Bertolini F, Finocchiaro G, Eoli M, Lang FF, Shinojima N, Gumin J, Takezaki T, Hossain A, Sevim H, Chung L, Wheeler HT, Baxter RC, McDonald KL, Alentorn A, Marie Y, Boisselier B, Carpentier C, Mokhtari K, Capelle L, Hoang-Xuan K, Sanson M, Delattre J, Idbaih A, Lathia J, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Carson C, Naik U, Hjelmeland A, Majumder S, Rich J, Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones DTW, Korshunov A, Tonjes M, Plass C, Jabado N, Pfister SM, Johansson M, Oudin A, Tiemann K, Bernard A, Keunen O, Fack F, Golebiewska A, Stieber D, Wang B, Hedman H, Niclou SP, Alexiou GA, Vartholomatos G, Karamoutsios A, Voulgaris S, Cho W, Patil S, Burzynski S, Mrowczynski E, Grela K, Moeckel S, Meyer K, Bosserhoff A, Spang R, Leukel P, Proescholdt M, Bogdahn U, Vollmann A, Hau P, Nakabayashi H, Shimizu K, Schroeteler J, Reeker R, Suero E, Stummer W, Ewelt C, Campos B, Gal Z, Baader A, Schneider T, Bageritz J, Schmoch T, Mogler C, Goidts V, Unterberg A, Herold-Mende CC, Hagemann C, Kessler AF, Fett S, Hofmann L, Monoranu CM, Al-Jomah N, Polat B, Patel R, Ernestus RI, Vince GH, Busek P, Balaziova E, Hilser M, Vomelova I, Fejfarova E, Sromova L, Sedo A, Kessler AF, Hagemann C, Hofmann L, Patel R, Linsenmann T, Ernestus RI, Vince GH, Sooman L, Ekman S, Bergqvist M, Gullbo J, Bergstrom S, Johansson M, Wu X, Blomquist E, Lennartsson J, Shimazu Y, Levallet G, Planchard G, Duguet AE, Emery E, Guillamo J, Geffrelot J, Zalcman G, Lechapt-Zalcman E, Sjostrom S, Ghasimi S, Broholm H, Brannstrom T, Johansen C, Collatz-Laier H, Henriksson R, Andersson U, Melin B, Kuratsu J, Nakamura H, Makino K, ducray F, meyronet D, Cartalat-Carel S, Guyotat J, Jouanneau E, Frappaz D, d'Hombres A, Sunyach M, Bauchet L, Honnorat J, Jaramillo E, Vargas C, Tze-Chun T, Huang S, Liu J, Hamdan A, Mitchell P, Flechl B, Ackerl M, Sax C, Oberndorfer S, Calabek B, Sizoo E, Reijenfeld J, Crevenna R, Preusser M, Marosi C, Rozumenko V, Khoroshun A, Rozumenko A, Fischbach P, Haquet A, Dutilleux A, Bracke J, Al Bassir M, Denoel C, Pace A, Villani V, Grattarola C, Di Napoli L, Maschio M, Benincasa D, Zucchella C, Burdukova YA, Vlasova EY, Gniteeva LN, Alekseeva OS, Voronin NA, Andreeva EV, Gorbatykh SV, Pavlova EV, Popov VE, Stroganova TA, Satoer DD, Kloet A, Vincent AJPE, Dirven CMF, Visch-Brink EG, Ungureanu G, Alexandra C, Ioana I, Paul M, Rares M, Oana M, Ioan Stefan F, Abdel Karim K, Abdel Wahab MM, Ezz LR, Abdel Raouf S, Shevtsov MA, Pozdnyakov AV, Kim AV, Samochernych KA, Guzhova IV, Romanova IV, Khachatryan WA, Margulis BA, Kleijn A, Kloezeman JJ, Treffers-Westerlaken EJ, Leenstra S, Dirven CMF, Debets R, Lamfers MML, Chirasani SR, Leukel P, Gronwald W, Gottfried E, Stadler K, Bogdahn U, Hau P, Kreutz M, Grauer OM, Persson BR, Engstrom P, Grafstrom G, Baureus Koch C, Widegren B, Salford LG, Gramatzki D, Peipp M, Staudinger M, Weller M, Hill LJ, Hossain-Ibrahim K, Logan A, Cruickshank GS, Pellegatta S, Eoli M, Antozzi C, Frigerio S, Cantini G, Bruzzone M, Anghileri E, Pollo B, Parati E, Finocchiaro G, Stragliotto G, Holm S, Adamson L, Giraud G, Hansson M, Henter J, Martinez-Garcia M, Villalonga R, Martinez-Soler F, Gimenez-Bonafe P, Acebes JJ, Casanovas O, Gil M, Tortosa A, Vinals F, Sander P, Leukel P, Vollmann-Zwerenz A, Jachnik B, Dobner C, Bogdahn U, Kalbitzer H, Hau P, Weissenberger J, Mutlu A, Hensel S, Senft C, Seifert V, Kogel D, Hossain-Ibrahim K, Hill LJ, Logan A, Cruickshank GS, Jung S, Wen M, Pei J, Jang W, Jung T, Kim I, Ishida J, Ichikawa T, Kurozumi K, Inoue S, Maruo T, Onishi M, Fujii K, Shimazu Y, Chiocca A, Date I, Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca E, Kaur B, Date I, Kang S, Sin G, Shim J, Lee S, Huh Y, Kim E, Chang J, Kim S, Hong Y, Kim D, Lefranc F, Verschuere T, De Witte O, Van Gool S, Kiss R, DeVleeschouwer S, Ewelt C, Ardon H, Suero E, Gunes D, Wolfer J, Fischer B, Stummer W, Thorsteinsdottir J, Fu P, Gehrmann M, Multhoff G, Tonn JC, Schichor C, Jachtenberg J, Bakker Schut T, Puppels G, French P, Kros M, Lamfers M, Leenstra S, Costello PC, McDonald W, MacDonald D, Zlatescu M, Megyesi J, Rossetto M, Gallego Perez-Larraya J, Boisselier B, Ciccarino P, Labussiere M, Marie Y, Delattre J, SANSON M, Ilhan-Mutlu A, Wohrer A, Berghoff AS, Widhalm G, Marosi C, Wagner L, Preusser M, Di Stefano A, Gallego Perez-Larraya J, Ducray F, Boisselier B, Labussiere M, Paris S, Cheneau C, Delattre J, Sanson M, Lonnqvist F, Gaillard PJ, Gladdines W, Boogerd W, van Tellingen O, Milojkovic Kerklaan B, Schellens JHM, Brandsma D, Denicolai E, Baeza-Kallee N, Tchoghandjian A, Beclin C, Figarella-Branger D, Rahman CV, Smith SJ, Morgan PS, Langmack KA, Macarthur DC, Rose FR, Shakesheff KM, Grundy RG, Rahman R, Nowosielski M, DiFranco MD, Putzer D, Seiz M, Jacobs AH, Stockhammer G, Hutterer M, Okada M, Shishido H, Hatakeyama T, Shinomiya A, Miyake K, Kawai N, Tamiya T, Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T, Alexiou GA, Tsiouris S, Papadopoulos A, Al-Bokharhli J, Kyritsis AP, Voulgaris S, Fotopoulos AD, Roelcke U, Boxheimer L, Fathi AR, Schwyzer L, Ortega M, Berberat J, Grobholz R, Remonda L, Oikawa M, Sato K, Ito T, Sugio H, Ozaki Y, Nakamura H, Schwyzer L, Berberat J, Boxheimer L, Remonda L, Roelcke U, Kozic D, Njagulj V, Gacesa JP, Prvulovic N, Semnic R, Basmaci M, Hasturk AE, Hasturk AE, Basmaci M, Bahr O, Weise L, Harter PN, Weiss C, Starzetz T, Steinbach JP, Mittelbronn M, Hattingen E, Price SJ, Young AMH, Thomas OM, Mohsen LA, Frary AJ, Lupson VC, McLean MA, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Grefkes C, Goldbrunner R, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Grefkes C, Goldbrunner R, Weiss C, Neuschmelting V, Eisenbeis A, Nettekoven C, Rehme A, Grefkes C, Goldbrunner R, Grech-Sollars M, Saunders DE, Phipps KP, Clayden JD, Clark CA, Schwyzer L, Berberat J, Boxheimer L, Remonda L, Roelcke U, Booth TC, Larkin T, Yuan Y, Kettunen M, Markowetz F, Scoffings D, Jefferies S, Brindle KM, Pica A, Hauf M, Slotboom J, Beck J, Schucht P, Aebersold DM, Wiest R, Pace A, Marzi S, Fabi A, Carapella CM, Giovinazzo G, Marucci L, Anelli V, Vidiri A, Riva M, Castellano A, Raneri F, Pessina F, Fava E, Falini A, Bello L, Gahramanov S, Muldoon LL, Varallyay CG, Li X, Kraemer DF, Fu R, Hamilton BE, Rooney WD, Neuwelt EA, Hawkins-Daarud A, Rockne R, Muzi M, Patridge S, Kinahan P, Swanson KR, Radbruch A, Fladt J, Wiestler B, Baumer P, Heiland S, Wick W, Bendszus M, Lwin M, Al-Salihi O, Sharpe G, Izmailov TR, Panshin GA, Datsenko PV, Kavsan VM, Balynska EV, Chernolovskaya EL, Zenkova MA, Buhl RM, Janz C, Gomez Gallego J, Albanna W, Rashidi A, Schmiegelow P, Buhl RM, Alexiou GA, Vartholomatos G, Karamoutsios A, Voulgaris S, Shen D, Wang J, Qiu Z, Chen F, Chen Z, Miwa K, Shinoda J, Ito T, Yokoyama K, Yamada M, Yamada J, Yano H, Iwama T, Brokinkel B, Schober O, Heindel W, Hargus G, Paulus W, Stummer W, Woelfer J, Aoki T, Arakawa Y, Ueba T, Miyatake S, Nozaki K, Taki W, Tsukahara T, Miyamoto S, Matsutani M, Satou K, Ito T, Takanashi M, Oikawa M, Ozaki Y, Sugio H, Nakamura H. Abstracts of the 10th Congress of the European Association of NeuroOncology. Marseille, France. September 6-9, 2012. Neuro Oncol 2012; 14 Suppl 3:iii1-109. [PMID: 22977921 DOI: 10.1093/neuonc/nos183] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Zhou T, Meng X, Xu B, Wei S, Chen X, De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS, Gonzalez JDSR, Alberto OV, Patricia HM, Chaichana K, Pendleton C, Chambless L, Nathan J, Camara-Quintana J, Li G, Harsh G, Thompson R, Lim M, Quinones-Hinojosa A, Oppenlander ME, Wolf A, Porter R, Nakaji P, Smith KA, Spetzler RF, Sanai N, Kim JH, Clark AJ, Jahangiri A, Sughrue ME, McDermott MW, Aghi MK, Chen C, Kasper E, Warnke P, Park CK, Lee SH, Song SW, Kim JW, Kim TM, Yamaguchi F, Omura T, Ten H, Ishii Y, Kojima T, Takahashi H, Teramoto A, Pereira EA, Livermore J, Ansorge O, Bojanic S, Meng X, Xu B, Chen X, Wei S, Zhou T, Tong H, Yu X, Zhou D, Hou Y, Zhou Z, Zhang J, Fabiano AJ, Rigual N, Munich S, Fenstermaker RA, Chen X, Meng X, Zhang J, Wang F, Zhao Y, Xu BN, Kim EH, Oh MC, Lee EJ, Kim SH, Kim YH, Kim CY, Kim YH, Han JH, Park CK, Kim SK, Paek SH, Wang KC, Kim DG, Jung HW, Chen X, Meng X, Wang F, Zhao Y, Xu BN, Krex D, Lindner C, Juratli T, Raue C, Schackert G, Valdes PA, Kim A, Leblond F, Conde OM, Harris BT, Paulsen KD, Wilson BC, Roberts DW, Krex D, Juratli T, Lindner C, Raue C, Schackert G, Occhiogrosso G, Cascardi P, Blagia M, De Tommasi A, Gelinas-Phaneuf N, Choudhury N, Al-Habib A, Cabral A, Nadeau E, Vincent M, Pazos V, Debergue P, DiRaddo R, Del Maestro RF, Guha-Thakurta N, Prabhu SS, Schulder M, Zavarella S, Nardi D, Schaffer S, Ruge MI, Grau S, Fuetsch M, Kickingereder P, Hamisch C, Treuer H, Voges J, Sturm V, Choy W, Yew A, Spasic M, Nagasawa D, Kim W, Yang I, Quigley MR, Hobbs J, Bhatia S, Cohen ZR, Shimon I, Hadani M, Carapella CM, Oppido PA, Vidiri A, Telera S, Pompili A, Villani V, Fabi A, Pace A, Cahill D, Wang M, Won M, Aldape K, Maywald R, Hegi M, Mehta M, Gilbert M, Sulman E, Vogelbaum M, Narayana A, Kunnakkat SD, Parker E, Gruber D, Gruber M, Knopp E, Zagzag D, Golfinos J, Dziurzynski K, Blas-Boria D, Suki D, Cahill D, Prabhu S, Puduvalli V, Levine N, Bloch O, Han SJ, Kaur G, Aghi MK, McDermott MW, Berger MS, Parsa AT, Quigley MR, Fukui O, Chew B, Bhatia S, DePowell JJ, Sanders-Taylor C, Guarnaschelli J, McPherson C, Sheth SA, Snuderl M, Kwon CS, Wirth D, Yaroslavsky A, Curry WT, Vogelbaum MA, Wang M, Hadjipanayis CG, Won M, Mehta MP, Gilbert MR, Megyesi JF, Macdonald D, Wang B, Pierre GHS, Hoover JM, Goerss SJ, Kaufmann TJ, Meyer FB, Parney IF, Guthikonda B, Thakur J, Khan I, Ahmed O, Shorter C, Wilson J, Welsh J, Cuellar H, Jeroudi M. SURGICAL THERAPIES. Neuro Oncol 2011; 13:iii154-iii163. [PMCID: PMC3222965 DOI: 10.1093/neuonc/nor164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2023] Open
|
18
|
Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, Carapella CM, Vidiri A, Muti P. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 2011; 258:2100-4. [PMID: 21674196 DOI: 10.1007/s00415-011-6132-8] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Revised: 05/24/2011] [Accepted: 05/30/2011] [Indexed: 10/18/2022]
Abstract
Lacosamide (LCM) is an antiepileptic drug (AED) that has demonstrated a good efficacy in controlling seizures as an add-on in adult epilepsy. To date, there have been no studies on LCM in patients with brain tumor-related epilepsy (BTRE). To evaluate efficacy and tolerability of LCM as an add-on in BTRE, we followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min < 1 max 10 months). Mean seizure number in the last month prior to the introduction of LCM had been 15.4. At last follow-up, the mean seizure number was reduced to 1.9/month. Lacosamide mean dosage was of 332.1 mg/day (min 100 max 400 mg/day). Responder rate was 78.6%. One patient discontinued LCM because of side-effects. There were no other reported side-effects. Preliminary data on the use of LCM in add-on in patients with BTRE indicate that this drug may represent a valid alternative as an add-on in this particular patient population. However, larger samples are necessary in order to draw definitive conclusions.
Collapse
Affiliation(s)
- M Maschio
- Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-Facial Pathology, National Institute for Cancer Regina Elena, Via Elio Chianesi 53, 00144 Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Maschio M, Dinapoli L, Saveriano F, Pompili A, Carapella CM, Vidiri A, Jandolo B. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 2009; 120:210-2. [PMID: 19719809 DOI: 10.1111/j.1600-0404.2009.01226.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Zonisamide (ZNS) is an antiepileptic drug (AED) with broad spectrum action that demonstrated a good efficacy in controlling seizures as add-on in adult and pediatric epilepsy. To date there have been no studies on ZNS in patients with brain tumor-related epilepsy (BTRE). AIM OF THE STUDY To evaluate efficacy and tolerability of ZNS as add-on in BTRE. METHODS We followed six patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Three patients underwent chemotherapy while being treated with ZNS. Mean duration of follow-up was 8 months. RESULTS Mean seizure number in the last month prior to the introduction of ZNS had been 27.7/month. ZNS mean dosage was of 283.3 mg/day. At last follow-up, the mean seizure number was reduced to 8.8/month. Responder rate was 83.3%.Two patients discontinued the drug because of side effects. There were no other reported side effects. CONCLUSIONS Preliminary data on the use of ZNS in add-on in patients with BTRE indicate that this drug may represent a valid alternative as add-on in this particular patient population. However, larger samples are necessary to draw definitive conclusions.
Collapse
Affiliation(s)
- M Maschio
- Center for Tumor-related Epilepsy, Department of Neuroscience and Cervical-Facial Pathology, National Institute for Cancer Regina Elena, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
20
|
Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, Giannarelli D, Occhipinti E, Jandolo B. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 2007; 86:61-70. [PMID: 17598071 DOI: 10.1007/s11060-007-9430-3] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2007] [Accepted: 05/31/2007] [Indexed: 10/23/2022]
Abstract
Epilepsy in brain tumor patients is often refractory to pharmacological treatments and can complicate the therapeutic management of these patients. We conducted a prospective, observational study. The aim of this study was to investigate the efficacy and tolerability of topiramate (TPM) in brain tumor associated epilepsy. We studied 47 patients with brain tumors and epilepsy. The entire group was administered AEDs. TPM was the first therapeutic choice in 14 patients, while in the remaining 33 patients previous AEDs were modified and TPM was introduced due to side effects or inefficacy of the first drug. Follow-up ranged from 3 to 48 months (mean 16.5 months). Considering the final follow-up of each patient who assumed TPM for at least 3 months, we observed 45 patients: 25 were seizure free (55.6%), 9 had a reduction of seizure frequency (SF) higher than 50% (20%) and 11 were stable (24.4%). TPM responder rate was 75.6%. Three patients (6.4%) discontinued TPM for severe side effects (1 after 4 months and 2 after 1 month) and 4 (8.5%) had mild and reversible side effects. In the group of patients who had been in therapy with other AEDs prior to entering the study (n = 33), 19 patients had side effects (57.6%). During follow-up, the haematological parameters were in the normative ranges. Tumor-related seizures are difficult to control with AEDs; the precise reasons for this difficulty are not yet clear. Using TPM, we obtained good seizure control with a low incidence of side effects.
Collapse
Affiliation(s)
- M Maschio
- Epilepsy Outpatient Center, Department of Neuroscience and Cervical-Facial Pathology, National Institute for Cancer Regina Elena, Via Elio Chianesi 53, Roma, 00144, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Fabi A, Felici A, Mirri MA, Metro G, Vidiri A, Pace A, Carosi MA, Cognetti F, Occhipinti E, Carapella CM. Fixed dose rate (FDR) gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): Preliminary results of a phase II study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.12502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12502 Background: In a previous phase I study (ASCO 2006), where FDR Gemcitabine at 10/mg/m2/min was tested in association with radiotherapy (RT) for the treatment of newly diagnosed GBM, a maximum tolerated dose of 175 mg/m2/wk was identified. Methods: After surgery for GBM (either citoreduction or sterebiopsy), patients were treated with fractionated focal RT at a daily dose of 2.0 Gy per fraction, five days per week for six weeks (total dose of 60 Gy). FDR Gemcitabine at 175 mg/m2/wk was given concomitantly starting 24–72 hours prior to RT and then for the whole duration of RT. An MRI performed at 7 and 40 days from the end of chemo-radiotherapy was used for activity assessment. Standard oral temozolamide 150–200 mg/m2 was administrated following the combined treatment. Results: From 07/2004 16 patients (9 male, 7 female) have been enrolled. Characteristics of patients were: median age 57 years (42–72), median KPS at baseline 90 (70–100), surgery/stereobiopsy 14/2. Median time from diagnosis to initiation of Gemcitabine was 45 days (28–54). Among the 14 evaluable patients 3 (21.4%) partial responses, 7 (50%) stable disease and 4 (28.5%) progressive diseases were recorded. At a median follow up of 18 months (2–33) time to progression was 6 months (1.5–24). Toxicity was manageable with only one G3 neutropenia and hypertransaminasemia in two patients respectively. Grade 1 hypertransaminasemia was registered in 6 patients (43%). Conclusions: These preliminary results show that in patients with newly diagnosed GBM, radiosensitizing FDR Gemcitabine at 175 mg/m2/wk is a well tolerated regimen with an interesting activity. Accrual is ongoing and final results will be presented at the meeting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Fabi
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Felici
- Regina Elena National Cancer Institute, Rome, Italy
| | - M. A. Mirri
- Regina Elena National Cancer Institute, Rome, Italy
| | - G. Metro
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Vidiri
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Pace
- Regina Elena National Cancer Institute, Rome, Italy
| | - M. A. Carosi
- Regina Elena National Cancer Institute, Rome, Italy
| | - F. Cognetti
- Regina Elena National Cancer Institute, Rome, Italy
| | | | | |
Collapse
|
22
|
Carapella CM, Mirri AM, Felici A, Vidiri A, Pace A, Carosi MA, Occhipinti EM, Arcangeli G, Cognetti F, Fabi A. Prolonged gemcitabine infusion as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): A phase I study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1581 Background: The use of cytotoxic drugs concurrent with RT represents a promising approach in the combined treatment of malignant gliomas. Gemcitabine (dFdCyd) is a drug widely explored for its potential radiomimetic activity in different tumors. The present study was aimed to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of weekly prolonged dFdCyd infusion, administered in combination with RT as first line treatment, in adult pts affected by supratentorial GBM. Methods: Within 6 weeks after surgery, in the presence of measurable residual disease and KPS >70, pts were treated with fractionated RT at a dose of 2.0 Gy/daily fractions, 5 days a week (global dose 60 Gy). From 24 to 72 hours before the first RT application, and afterwards once weekly, pts received concurrent dFdCyd, at fixed dose rate of 10 mg/m2/min, over a total period of six weeks. Planned dose levels of dFdCyd started from 200 mg/m2/weekly (level 1), with sequential steps of 25 mg/m2/w based on toxicity. Results: Ten pts were enrolled into the study: six were male, median age 55.2 years (range 44–75), with a median KPS at baseline of 85 (SD 9.71). The median time from diagnosis to the start of treatment was six weeks (range 4–7). The median RT duration was 6 weeks (range 4–7), all but one pt received the planned dose and all pts received concomitant CT. Four pts entered at Level 1; one pt was excluded from the study, due to rapid progressive disease during the treatment. Two of the three valuable pts presented a relevant neurological worsening; on this basis the dFdCyd dose was reduced to 175 mg/m2/w (Level -1). A total of six pts were entered at Level -1, and none of them reported DLT. No hematological grade 3–4 toxicity was reported. Grade 3 non-hematological toxicity was observed in one pt (transaminases increase). After a median follow-up of 13.4 months (range 3–24), the median progression-free survival was 8 months (CI 95% 1–18), and the median overall survival was 14 months (CI 95% 12–17). Conclusions: The recommended dose of prolonged infusion of dFdCyd concomitant with RT is 175 mg/m2/w. The observed activity has been considered interesting enough to support a phase II study of this concurrent CT-RT schedule as first line treatment in GBM. [Table: see text]
Collapse
Affiliation(s)
| | - A. M. Mirri
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Felici
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Vidiri
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Pace
- Regina Elena National Cancer Institute, Rome, Italy
| | - M. A. Carosi
- Regina Elena National Cancer Institute, Rome, Italy
| | | | - G. Arcangeli
- Regina Elena National Cancer Institute, Rome, Italy
| | - F. Cognetti
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Fabi
- Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
23
|
Vidiri A, Carapella CM, Pace A, Mirri A, Fabi A, Carosi M, Giannarelli D, Pompili A, Jandolo B, Occhipinti E, Di Giovanni S, Crecco M. Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas. J Exp Clin Cancer Res 2006; 25:177-82. [PMID: 16918127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Forty-seven patients with Glioblastoma (42) and Anaplastic Astrocytoma (5) were studied with MR 24 hrs after surgery. In order to evaluate the role of early MR in defining the extent of surgical resection and its relation with the prognosis of malignant glioma patients, three categories of surgical resection were considered: gross total, sub-total and partial resection. The results were correlated with progression-free survival (PFS) and overall survival (ST). As demonstrated by early-MR, gross total resection was performed in 17 patients, sub-total and partial resection in 19 and 11 patients, respectively. The PFS was 6 months in gross total resection, 6 and 3 months in sub-total and in partial resection, respectively. The median survival time was 16 months in total resection patients, 13 months and 7 months in sub-total resection and partial resection patients, respectively. The study confirms that early-MR has to be considered an accurate technique for monitoring the extension of malignant glioma surgical resection and shows a good correlation between early-MR findings, PFS and ST.
Collapse
Affiliation(s)
- A Vidiri
- Department of Diagnostic Imaging, Regina Elena Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pace A, Pompili A, Maschio M, Galie' E, Telera S, Jandolo B, Occhipinti E, Carapella CM. PCV and/or TMZ chemotherapy in 255 gliomas. Analysis of the clinical experience from a neuro-oncology data-base. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Pace
- Regina Elena Nat. Cancer Inst., Rome, Italy
| | - A. Pompili
- Regina Elena Nat. Cancer Inst., Rome, Italy
| | - M. Maschio
- Regina Elena Nat. Cancer Inst., Rome, Italy
| | - E. Galie'
- Regina Elena Nat. Cancer Inst., Rome, Italy
| | - S. Telera
- Regina Elena Nat. Cancer Inst., Rome, Italy
| | - B. Jandolo
- Regina Elena Nat. Cancer Inst., Rome, Italy
| | | | | |
Collapse
|
25
|
Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14:1722-6. [PMID: 14630675 DOI: 10.1093/annonc/mdg502] [Citation(s) in RCA: 214] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The optimal treatment for low-grade glioma (LGG) is still controversial. Recent data indicate a potential influence of chemotherapy on the natural evolution of these tumors, allowing for the deferral of more aggressive therapies. PATIENTS AND METHODS Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression. McDonald's response criteria were utilized to evaluate TMZ activity. Thirty patients (69.7%) had previously received radiotherapy; 16 (37.2%) had received prior chemotherapy. Clinical benefit was evaluated measuring seizure control, reduction in steroid dose and modification of Karnofsky performance status and Barthel index. Quality of life was assessed with the QLQ-C30 questionnaire. RESULTS We observed a complete response in four patients, 16 partial responses, 17 stable disease (with four minor response) and six progressive disease. Median duration of response was 10 months [95% confidence interval (CI) 8-12], with a 76% rate of progression free survival (PFS) at 6 months, and a 39% rate of PFS at 12 months. A relevant clinical benefit was observed particularly in patients presenting epilepsy. CONCLUSIONS The high response rate of 47% (95% CI 31% to 61%) confirms that TMZ chemotherapy is a valid option in the treatment of progressive LGG. The present preliminary results seem interesting and warrant further evaluation of TMZ clinical activity in a larger series of progressive LGG.
Collapse
Affiliation(s)
- A Pace
- Department of Neuroscience, Regina Elena National Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Cianciulli AM, Morace E, Coletta AM, Occhipinti E, Gandolfo GM, Leonardo G, Carapella CM. Investigation of genetic alterations associated with development and adverse outcome in patients with astrocytic tumor. J Neurooncol 2000; 48:95-101. [PMID: 11083072 DOI: 10.1023/a:1006420921159] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Models describing progression in the genetic derangement of glial tumors have shown chromosomal loss and gain occurring most frequently in high-grade lesions, suggesting that identification of these aberrations may be prognostically significant. In this study, Fluorescence in situ hybridization (FISH) has been used to determine, and to confirm, loss and gain of chromosomes 1, 8, 10, 12 and 17, in formalin-fixed, paraffin-embedded brain biopsy tissue taken from 60 brain gliomas submitted to surgical resection or stereotactic biopsy. FISH analysis may be a valuable adjunct to histological grading. The results showed that this molecular cytogenetic technique is an important clinical and experimental tool that provides new insight on genetic alterations, confirming gain and loss of genetic material that occurs at the initiation and progression of human glioma. Our data suggests that potentially useful prognostic information may be obtained through this approach. Monosomy 10 was the most statistically significant negative predictor of patient survival, showing a significant correlation with the histological grading.
Collapse
Affiliation(s)
- A M Cianciulli
- Department of Clinical Pathology, Regina Elena Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
27
|
Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, Raus L, Occhipinti E, Jandolo B. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17:479-82. [PMID: 10089071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
One hundred and nineteen consecutive patients affected by supratentorial gliomas were studied in order to determine the incidence of seizure at diagnosis, the occurrence of subsequent seizures and the efficacy of anticonvulsant treatment. The overall incidence of seizures as presentation symptom was 52% (62 patients). Preoperative seizures were present in 83% of patients affected by low-grade astrocytoma, in 46% of patients affected by anaplastic astrocytoma and in 36% of patients affected by glioblastoma. Postoperative epilepsy refractory to anticonvulsant treatment significantly related to low-grade histology and presence of preoperative seizures occurred in 48% of patients. Adverse effects associated with anticonvulsants were observed in 33.8% of patients treated with phenobarbital, 14.3% in the group treated with carbamazepine and 12% of patients treated with vigabatrin. We conclude that anticonvulsant treatment in patients affected by gliomas is often ineffective and prophylactic treatment should be discontinued after 6 months in patients preoperative seizures free. In patients with high risk of seizures antiepileptic drugs with good efficacy and lower incidence of adverse effects than phenobarbital are indicated.
Collapse
Affiliation(s)
- A Pace
- Neurology Service, Istituto Regina Elena, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Mottolese M, Natali PG, Coli A, Bigotti G, Benevolo M, Cione A, Raus L, Carapella CM. Comparative analysis of proliferating cell nuclear antigen and epidermal growth factor receptor expression in glial tumours: correlation with histological grading. Anticancer Res 1998; 18:1951-6. [PMID: 9677449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The present study analyzed the combined immunostaining for proliferating cell nuclear antigen (PCNA) and epidermal growth factor receptor (EGFR) with the aim of obtaining an objective method for the evaluation of the growth fraction in human glial tumors. A retrospective study was undertaken on 157 gliomas employing MoAb PC10 and MoAb 108, recognizing a 36 Kd nuclear protein associated with the cell cycle and the extracellular domain of the EGFR, respectively. The results of this immunohistochemical analysis showed that the rate of PCNA positive cell is directly associated to EGFR expression and significantly (P < 0.0001) correlates with tumor morphological grading, this was also the case in patients submitted to multiple surgical treatments for recurrent tumors. PCNA and/or EGFR are expressed by a minority of low grade astrocytoma, while anaplastic astrocytoma and glioblastoma displayed an intense immunoreactivity for the two antigens in more than 85% of tested cases. These findings indicate that the combined evaluation of PCNA and EGFR could allow a more definite biopathological grading of neuroepithelial brain tumours.
Collapse
Affiliation(s)
- M Mottolese
- Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Floris R, Crecco M, Gagliarducci L, Carapella CM, Nardocci M, Salvatore C, Simonetti G. [Magnetic resonance features in cerebral primary lymphomas in non-immunocompromised subjects]. Radiol Med 1997; 93:236-41. [PMID: 9221416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In the past few years, non-Hodgkin's lymphomas have been paid increasing attention to because of their recently increasing frequency. We reviewed the MR images of 17 patients with histologically proved primary CNS lymphoma, all of them immunocompetent at diagnosis. We studied the site, number and shape of the lesions, the presence and grade of edema and possible periventricular spread. The exams were performed with 0.5 T and 1.5 T MR units, using SE sequences on the sagittal, axial and coronal planes, before and after Gd-DTPA administration. The most typical neuroradiologic signs which may suggest the diagnosis of CNS lymphoma are deep or periventricular lesion site, diffuse and marked contrast enhancement, poorly defined borders, moderate edema surrounding the mass and a tendency to periventricular spread. MRI demonstrated 35 lesions in 17 patients. The lymphoma was unifocal in 9 cases (53%) and 7 lesions were localized in subtentorial site. Lesion size did not exceed 2 cm in 49% of cases, ranged 2-4 cm in 40% and exceeded 4 cm in 11% of cases only. These lesions and hypo- to isointense on T1-weighted images (97%) and their signal intensity varies on T2-weighted images, with mainly iso-/hypointense patterns (79%). All lesions enhanced after Gd-DTPA administration, 74% of them markedly and 26% moderately; enhancement was mostly homogeneous (80% of cases). Perilesional edema was observed in 74% of cases. In conclusion, MRI yields some useful information for the diagnosis of primary CNS lymphoma, but the clinical and radiologic signs of this lesion may exhibit aspecific signal features, meaning that no correct diagnosis can be made even in immuno-competent patients.
Collapse
Affiliation(s)
- R Floris
- Istituto di Radiologia, Università Tor Vergata Roma
| | | | | | | | | | | | | |
Collapse
|
30
|
Carapella CM, Carpinelli G, Knijn A, Raus L, Caroli F, Podo F. Potential role of in vitro 1H magnetic resonance spectroscopy in the definition of malignancy grading of human neuroepithelial brain tumours. Acta Neurochir Suppl 1997; 68:127-32. [PMID: 9233428 DOI: 10.1007/978-3-7091-6513-3_24] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The increasing sensitivity of neuro-imaging in the diagnosis of brain expanding lesions is not directly related to biopathological specificity and new technological approaches are under study. In particular Magnetic Resonance Spectroscopy (MRS) allows evaluation of some biochemical pathways whose metabolic alterations may be correlated with the nature and malignancy grading of primary brain tumours. In the present study the author performed an in vitro high field 1H MRS (9.4 and 14.1 T) analysis of specimens obtained from stereotactic biopsy or microsurgical removal of primary brain tumours. Different samples derived from heterogeneous areas and/or infiltrated perilesional regions were examined. This study was principally focused on malignancy grading of gliomas and its correlation with the ratio (R) between the resonance band arising from choline containing compounds (between 3.14 and 3.35 ppm) and the total creatine signal (3.0 ppm). Analyses allowed significant discrimination between astrocytomas (R = 2.4 +/- 0.6) and glioblastoma (GBM) (R = 4.4 +/- 1.3) [p < 0.002]; however the results did not allow discrimination between differentiated and anaplastic astrocytomas. The GBM showed the largest spread of values corresponding to their higher level of tissue heterogeneity and de-differentiation. Studies on non astrocytic brain tumours indicated that even higher R values were exhibited by oligodendrogliomas, even in well differentiated forms (p < 0.02 with respect to GBM). Moreover, preliminary observations indicated that signals arising from other metabolites may also contribute to a differential diagnosis of different oncotypes. Among these glycine appears particularly relevant, since higher levels were measured for this amino acid in GBM with respect to both astrocytomas and oligodendrogliomas.
Collapse
Affiliation(s)
- C M Carapella
- Department of Neurosurgery, Istituto Nazionale Tumori Regina Elena, Roma, Italy
| | | | | | | | | | | |
Collapse
|
31
|
Carpinelli G, Carapella CM, Palombi L, Raus L, Caroli F, Podo F. Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. Anticancer Res 1996; 16:1559-63. [PMID: 8694526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
In vitro high resolution 1H NMR spectroscopy allows non-invasive metabolic evaluation of specimens derived from surgically biopsied or resected brain tumors, with the aim of identifying potential markers of different malignancy grading, and improving diagnostic and therapeutic strategies. In the present study we evaluated 36 patients affected by different brain gliomas (7 well differentiated astrocytomas, 7 anaplastic astrocytomas, 16 glioblastomas, 6 oligodendrogliomas). These analyses allowed discrimination between well differentiated and anaplastic astrocytomas (AII + AA) and glioblastoma multiforme (GM) samples on the basis of the ratio between the integrated choline-containing resonance (b"Cho") and the creatine peaks (creatine (Cr) + Phosphocreatine (PCr)). While no definite difference was found between AII and AA, significantly higher values were observed for this ratio in GM. Other signals, derived from different metabolites, such as Glycine (Gly) and N-acetyl-aspartate (NAA), may also assume relevance in differential tumor diagnosis. In this study an increased [Gly]/[Cr + PCr] ratio was observed in GM with respect to AII and AA. The NAA levels observed in our tumor specimens may be explained on the basis of tumor cell infiltration into brain adjacent tissue. Interesting, but inconclusive, are the data concerning oligodendrogliomas, which, also in well differentiated forms, exhibit increased levels of b"Cho"/(Cr + PCr) ratio. The present study confirms the role of MRS in the biochemical characterization of neoplastic brain tissue and its potential contribution to a better selection of multidisciplinary treatment strategies.
Collapse
Affiliation(s)
- G Carpinelli
- Department of Cell Biology, Istituto Superiore di Sanità, Roma, Italy
| | | | | | | | | | | |
Collapse
|
32
|
Maini CL, Sciuto R, Tofani A, Ferraironi A, Carapella CM, Occhipinti E, Mottolese M, Crecco M. Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nucl Med Commun 1995; 16:756-66. [PMID: 7478408 DOI: 10.1097/00006231-199509000-00006] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using 111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of 111In-octreotide. An uptake index was computed using tumour/non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immunohistochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe 111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post-surgical follow-up and in the assessment of differentiation in glial tumours.
Collapse
Affiliation(s)
- C L Maini
- Department of Nuclear Medicine, Regina Elená National Cancer Institute, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Maini CL, Cioffi RP, Tofani A, Sciuto R, Fontana M, Carapella CM, Crecco M. Indium-111 octreotide scintigraphy in neurofibromatosis. Eur J Nucl Med 1995; 22:201-6. [PMID: 7789392 DOI: 10.1007/bf01081513] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Scintigraphy with the radiolabelled somatostatin analogue indium-111-DTPA-D-Phe-1-octreotide has recently been proposed for the imaging of CNS neoplasms expressing somatostatin receptors. While meningiomas are imaged with high sensitivity, neurinomas do not take up octreotide owing to the lack of somatostatin receptors. Neurofibromatosis is a relatively uncommon disorder in which meningiomas and neurinomas often occur in the same patient. Differential diagnosis between these two tumours by computed tomography and magnetic resonance imaging can be difficult. This study reports on 111In-octreotide scintigraphy in four patients with neurofibromatosis. 111In-octreotide scintigraphy was shown to be very helpful in the in vivo differential diagnosis: all four meningiomas showed intense tracer uptake, while all 15 neurinomas were negative (P < 0.001 by Fisher's exact test). It may be concluded that scintigraphy with 111In-octreotide is a useful diagnostic procedure in neurofibromatosis, complementing standard neuroradiological imaging procedures.
Collapse
Affiliation(s)
- C L Maini
- Nuclear Medicine Department, Regina Elena National Cancer Institute, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
34
|
Paggi MG, Martelli F, Fanciulli M, Felsani A, Sciacchitano S, Varmi M, Bruno T, Carapella CM, Floridi A. Defective human retinoblastoma protein identified by lack of interaction with the E1A oncoprotein. Cancer Res 1994; 54:1098-104. [PMID: 8313367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Inactivating mutations of the retinoblastoma susceptibility gene (Rb) are involved in the pathogenesis of hereditary and sporadic retinoblastoma. Alterations in the Rb gene have also been found in several other human tumors occurring with epidemiological incidence higher than that of retinoblastoma. Four human malignant glioma cell lines were examined for abnormalities in the retinoblastoma gene product (pRb), using a procedure based on the interaction of pRb with an in vitro-translated adenovirus E1A oncoprotein. In the CRS-A2 cell line, derived from a glioblastoma multiforme, pRb did not bind with the in vitro-translated E1A protein. Restriction analysis of the CRS-A2 Rb gene and Rb mRNA expression provided patterns that could not be distinguished from the other glioma cell lines. Further investigation revealed the presence of a truncated pRb in the CRS-A2 cell line, due to a nucleotide insertion in the coding sequence at position 2550. In addition, this truncated Rb protein was undetectable in phosphorylated form. The binding assay with the in vitro-translated E1A was also used to study other cell lines with known mutations in the Rb gene. This method, which evaluates the interaction between in vitro-translated E1A and the pRb, is proposed as a rapid screening for detecting functional alterations in the retinoblastoma protein.
Collapse
Affiliation(s)
- M G Paggi
- Laboratori di Metabolismo Cellulare e Farmacocinetica, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Derlon JM, Petit-taboué MC, Dauphin F, Courtheoux P, Chapon F, Creissard P, Darcel F, Houtteville JP, Kaschten B, Sadzot B, Stevenaert A, Tjuvajev JG, Macapinlac HA, Daghighian F, Ginos JZ, Finn RD, Jiaju Zhang MS, Beattie B, Graham M, Larson SM, Blasberg RG, Levivier M, Goldman S, Pirotte B, Brucher JM, Balériaux D, Luxen A, Hildebrand J, Brotchi J, Go KG, Kamman RL, Mooyaart EL, Heesters MAAM, Sijens PE, Oudksrk M, van Dijk P, Levendag PC, Vecht CJ, Metz RJ, Kennedy DN, Rosen BR, Hochberg FH, Fishman AJ, Filipek PA, Caviness VS, Gross MW, Weinzierl FX, Trappe AE, Goebel WE, Frank AM, Becker G, Krone A, Schmidt K, Hofmann E, Bogdahn U, Bencsch H, Fclber S, Finkenstedt G, Kremser C, Sfockhammer G, Aichner F, Bogdahn U, Fröhlich T, Becker G, Krone A, Schlief R, Schürmann J, Jachimczak P, Hofmann E, Roggendorf W, Roosen K, Carapella CM, Carpinelli G, Passalacqua R, Raus L, Giannini M, Mastrostefano R, Podo F, Tofani A, Maslrostefano R, Mottoles M, Ferraironi A, Scelsa MG, Oppido P, Riccio A, Maini CL, Collombier L, Taillandier L, Dcbouverie M, Laurens MH, Thouvenot P, Weber M, Bertrand A, Cruickshank GS, Patterson J, Hadley D, De Witte O, Hildebrand J, Luxen A, Goldman S, Reifenberger J, Liu L, James CD, Wechsler W, Collins VP, Fabel-Schulte K, Jachimczak P, Heßdörfer B, Baur I, Schlingensiepen KH, Ernestus RI, Brysch W, Bogdahn U, Blesch A, Bosserhoff AK, Apfel R, Lottspeich F, Jachimczak P, Büttner R, Bogdahn U, Cece R, Bockhorst K, Barajon I, Tazzari S, Cavaletti G, Torri-Tarelli L, Tredici G, Hecht B, Turc-Carel C, Atllas R, Chatel M, Gaudray P, Eis M, Gioanni J, Hecht F, Balledux J, Rothbart D, Criscuolo GR, de Campos JM, Kusak ME, Rey JA, Bello MJ, Sarasa JL, Els T, Dubois F, Blond S, Parent M, Assaker R, Gosselin P, Christiaens JL, Feld R, Moringlane JR, Steudel WI, Schaudies JR, Hoehn-Berlage M, Janka M, Tonn JC, Fischer U, Meese E, Roosen K, Remmelink M, Salmon I, Cras P, Pasteels JL, Brotchi J, Gliese M, Kiss R, Bensadoun RJ, Frenay M, Formento JL, Milano G, Lagrange JL, Grellier P, Lee JY, Ernestus RI, Riese HH, Fründ R, Cervós-Navarro J, Reutter W, Lippitz B, Scheitinger C, Scholz M, Weis J, Gilsbach JM, Füzesi L, Koochekpour S, Merzak A, Geissler A, Pilkington GJ, Sanson M, Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Hamelin R, Van de Kelft E, Dams E, Martin JJ, Woertgen C, Willems P, Lehrke R, Voges J, Treuer H, Erdmann J, Müller RP, Sturm V, Wurm RE, Warrington AP, Laing RW, Holzschuh M, Sardell S, Hines F, Graham JD, Brada M, Ushio Y, Kuratsu JI, Kochi M, Kitz K, Aichholzer M, Rössler K, Goldman S, Alesch F, Ertl A, Sorensen PS, Helweg-Larsen S, Mourldsen H, Hansen HH, El Sharoum SY, Berfelo MW, Theunissen PHMH, Jager JJ, Levivier M, de Jong JMA, Fedorcsák I, Nyáry I, Osztie É, Horvath Á, Kontra G, Frenay M, Burgoni-chuzel J, Paquis P, Lagrange JL, Pirotte B, Helweg-Larsen S, Hansen SW, Sørensen PS, Salmon I, Kiss R, Krauseneck P, Müller B, Morche M, Tonn JC, Lagerwaard FJ, Brucher JM, Levendag PC, Eijkenboom WMH, Schmilz PIM, Lentzsch S, Weber F, Franke J, Dörken B, Lunardi P, Schettini G, Osman FJ, Luxen A, Qasho R, Mocellini C, Ruda R, Soffietti R, Garabello D, Sales S, De Lucchi R, Vasario E, Schiffer D, Muracciole X, Brotchi J, Régis J, Manera L, Peragut JC, Juin P, Sedan R, Nieder C, Niewald M, Walter K, Schnabel K, Nieder C, Hildebrand J, Niewald N, Nestle U, Schnabel K, Berberich W, Oschmann P, Theißen RD, Reuner KH, Kaps M, Dorndorf W, Martin KK, Hausmann O, Akinwunmi J, Rooprai HK, Kennedy A, Linke A, Ognjenovic N, Pilkington GJ, Svadovsky AI, Peresedov VV, Bulakov AA, Butyalko MY, Merlo A, Zhirnova IG, Labunsky DA, Gnazdizky VV, Gannushkina IV, Taphoorn MJB, Potman R, Barkhof F, Weerts JG, Karim ABMF, Heimans JJ, Jerrnann E, van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A, van der Sande JJ, Boogerd W, Kröger R, Jäger A, Wismeth C, Dekant A, Uirich J, Brysch W, Schlingensiepen KH, Jachimczak P, Bogdahn U, Pirolte B, Cool V, Gérard C, Levivier M, Dargent JL, Goldman S, Chiquet-Ehrismann R, Brotchi J, Hildebrand J, Velu T, Herrlinger U, Schabet M, Ohneseit P, Buchholz R, Zhu J, Reszka R, Weber F, Müller J, Walther W, Zhang LI, Brock M, Roosen N, Rock JP, Zeng H, Feng J, Fenstermacher JD, Rosenblum ML, Siegal T, Mäcke H, Gabizon A, Beljanski M, Crochet S, Bergenheim AT, Zackrisson B, Elfverson J, Bergström P, Henriksson R, Butti G, Baetta R, Gratzl O, Magrassi L, De Renzis MR, Soma MR, Davegna C, Pezzotta S, Paoletti R, Fumagalli R, Infuso L, Sankar AA, Darling JL, Herholz K, Thomas DGT, Defer GL, Brugières P, Gray F, Chomienne C, Poirier J, Degos L, Degos JD, Colombo BM, DiDonato S, Ghaemi M, Finocchiaro G, Hebeda KM, Sterenborg HJCM, Saarnak AE, Wolbers JG, van Gemert MJC, Kaaijk P, Troost D, Leenstra S, Das PK, Würker M, Bosch DA, Kostron H, Hochleitner BW, Obwegeser A, Ortler M, Seiwald M, Vooys W, Krouwer HGJ, de Gast GC, Marx JJM, Pietrzyk U, Osman FJ, Lunardi P, Puzzilli F, Menovsky T, Beek JF, Wolbers JG, van Gemert MJC, Naujocks G, Wiestler OD, Schirrmacher V, Heiss WD, Schramm J, Schmitz A, Eis-Hübinger AM, Piepmeier PH, Pedersen P, Greer C, Quigley MR, Shih T, Elrifal A, Rothfus W, Kotitschke K, Maroon JC, Rohertson L, Rampling R, Whoteley TL, Piumb JA, Kerr DJ, Falina PA, Crossan IM, Roosen N, Rock JP, Brandl M, Feng J, Zeng H, Ho KL, Fenstermacher JD, Rosenblum ML, Ruchoux MM, Vincent S, Jonca F, Plouet J, Lecomte M, Tonn JC, Samid D, Thibault A, Ram Z, Oldfield EH, Myers CE, Reed E, Schabet M, Herrlinger U, Buchholz R, Shoshan Y, Haase A, Siegal T, Siegal T, Shezen E, Siegal T, Stockhammer G, Rosenblum M, Samid D, Lieberman F, Terzis AJA, Bjerkvig R, Bogdahn U, Laerum OD, Arnold H, Thibault A, Samid D, Figg WD, Myers CE, Reed E, Thomas R, Flux G, Chittenden S, Kotitschke K, Doshi P, Brazil L, Thomas DGT, Bignor D, Zalutsky M, Brada M, Tjuvajev J, Kaplitt M, Desai R, Bradley MS, Muigg S, Bettie BS, Gansbacher B, Blasberg R, Haugland HK, Saraste J, Rooseni K, Laerum OD, Vincent AJPE, Avezaat CJJ, Bout A, Felber S, Noteboom JL, Vecht CH, Valerio D, Hoogerbrugge PM, Weber F, Reszka R, Zhu J, Walther W, List J, Schulz W, Aichner F, Wolbers JG, Sterenborg IIJCM, Kamphorst W, van Gemert MJC, van Alplien HAM, Salander P, Bergenheim T, Henriksson R, Grant R, Brazil L, Haase A, Thomas R, Guerrero D, Laing R, Ashley S, Brada M, Schmidt B, Bauer B, Grau G, Bohnstedt T, Frydrych A, Bogdahn U, Franz K, Lorenz R, Brandes A, Amanzo PD, Zampieri P, Rigon A, Scelzi E, Rotilio A, Berti F, Paccagnella A, Krone A, Fiorentino MV, Müller B, Krauseneck P, van Deventer PL, Dellemijn PLI, van den Bent MJ, Vecht CJ, Kansen PJ, Tredici G, Petruccioli NG, Becker G, Cavaletti G, Cavalletti E, Kiburg B, Müller LJ, Moorer-van Delft CM, Heimans JJ, Boer HH, Pace A, Bove L, Pietrangeli A, Woydt M, Innocenti P, Aloe A, Nardi M, Jandolo B, Kellie SJ, De Graaf SSN, Bloemhof H, Roebuck D, Dalla PL, Uges DDR, Roggendorf W, Johnston I, Besser M, Chaseling RA, Koeppen S, Gründemann S, Lossos A, Siegal T, Nitschke M, Vieregge P, Reusche E, Hofmann E, Rob P, Kömpf D, Postma TJ, Vermorken JB, Heimans JJ, Rampling RP, Dunlop DJ, Steward MS, Campbell SM, Roy S, Bogdahn U, Hilkens PHE, Verweij J, van Putten WLJ, Vecht CJ, van den Bent MJ, Hilkens PHE, Moll JWB, van der Burg MEL, Planting AST, van Putten WLJ, Roosen K, Vecht CJ, van den Bent MJ, Wondrusch E, Zifko U, Drlicek M, Liszka U, Grisold W, Zifko U, Fazeny B, Dittrich C, Lanfermann H, Wondrusch E, Grisold W, Verschuuren JJ, Meneses PI, Rosenfeld MR, Kaplitt MG, Posner JB, Dalmau J, Sillevis Smitt PAE, Manley G, Heindel W, Posner JB, Cavaletti G, Bogliun G, Margorati L, Bianchi G, Drlicek M, Liska U, Casati B, Kolig C, Grisold H, Kugel H, Graus F, Reñe R, Uchuya M, Valldeoriola F, Delattre JY, Benedetti de Cosentiro C, Ortale D, Martinez R, Lambre J, Cagnolati S, Erneslus RI, Vinai C, Salmaggi A, Nemni R, Silvani A, Forno MG, Luksch R, Confalonieri P, Boiardi A, Nitschke M, Scholz J, Röhn G, Vieregge P, Kömpf D, Hochberg FH, Pfeiffer G, Netzer J, Hansen C, Eggers C, Hagel C, Kunze K, Verschuuren JJ, Lackner K, Rosenblum MK, Lieberman FS, Posner JB, Dalmau J, Metz RJ, Kennedy DN, Pardo FS, Kutke S, Sorensen AG, Hochberg FH, Fishman AJ, Filipek PA, Rosen BR, Caviness VS, Mechtler LL, Withiam-Lench S, Shin K, Klnkel WR, Patel M, Truax B, Kinkel P, Shin K, Mechtler L, Ricci M, Pantano P, Maleci A, Pierallini S, Di Stefano D, Bozzao L, Cantore GP, Röhn G, Els T, Schröder R, Hoehn-Berlage M, Ernestus RI, Ruda R, Mocellini C, Soffietti R, Campana M, Ropolo R, Riva A, de Filippi PG, Schiffer D, Salgado D, Rodrigues M, Salgado L, Fonseca AT, Vieira MR, Bravo Marques JM, Satoh H, Uozumi T, Kiya K, Kurisu K, Arita K, Sumida M, Ikawa F, Tzuk-Shina T, Gomori JM, Rubinstein R, Lossos A, Siegal T, Vaalburg W, Paans AMJ, Willemsen ATM, van Waarde A, Pruim J, Visser GM, Go KG, Valentini S, Ting YLT, De Rose R, Chidichimo G, Corricro G, van Lcycn-Pilgram K, Erncslus RI, Klug N, van Leyen-Pilgram K, Ernestus RI, Schröder R, Klug N, Woydt M, Krone A, Tonn JC, Becker G, Neumann U, Roggendorf W, Roosen K, Plate KH, Breier G, Millaucr B, Weich HA, Ullrich A, Risau W, Roosen N, Chopra RK, Mikkelsen T, Rosenblum SD, Yan PS, Knight R, Windham J, Rosenblum ML, Schiffer D, Attanasio A, Cavalla P, Chio A, Giordana MT, Migheli A, Amberger V, Hensel T, Schwab ME, Cervoni L, Celli P, Tarantino R, Huettner C, Tonn JC, Berweiler U, Roggendorf W, Salmon I, Rorive S, Rombaut K, Pirotte B, Haot J, Brotchi J, Kiss R, Maugard-Louboutin C, Charrier J, Fayet G, Sagan C, Cuillioere P, Ricolleau G, Martin S, Menegalli-Bogeelli D, Lajat Y, Resche F, Molnàr P, Bárdos H, Ádány R, Rogers JP, Pilkington GJ, Pollo B, Giaccone G, Allegranza A, Bugiani O, Prim J, Badia J, Ribas E, Coello F, Shezen E, Lossos A, Abramsky O, Siegal T, Scerrati M, Roselli R, Iacoangeli M, Pompucci A, Rossi GF, Deeb SMA, Koreich O, Yaqub B, Moutaery KRA, Giordana MT, Cavalla P, Chio A, Marino S, Vigliani MC, Schiffer D, Deburghgraeve V, Darcel F, Gedouin D, Hassel MB, Guegan Y, Jeremic B, Grujicic D, Antunovic V, Matovic M, Shibamoto Y, Kallio M, Huhmar H, Kudoh C, Detta A, Sugiura K, Hitchcock ER, Mastrostefano R, Di Russo R, Cipriani§ M, Occhipinti EM, Conti EMS, Clowegeser A, Ortler M, Seiwald M, Kostron H, Rajan B, Ross G, Lim C, Ashlcy S, Goode D, Traish D, Brada M, Sanden GACV, Schouten LJ, Coebergh JWW, Razenberg PPA, Twijnstra A, Snilders-Keilholz A, Voormolen JHC, Hermans J, Leer JWH, Taillandier L, Baylac F, Dcbouvcrie M, Anxionnal R, Bracard S, Vignand JM, Duprcz A, Weber M, Winking M, Böker DK, Simmet T, Rothbart D, Strugar J, Balledux J, Criscuolo GR, Jachimczak P, Blesch A, Heβdörfer B, Bogdahn U, Ernestus RI, Schröder R, Klug N, Krouwer HGJ, Duinen SGV, Algra A, Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J, Newlands ES, O'Reilly SM, Brampton M, Soffietti R, Chio A, Mocellini C, Ruda R, Vigliani MC, Schiffer D, Sciolla R, Seliak D, Henriksson R, Bergenheim AT, Björk P, Gunnarsson PO, Hariz M, Grant R, Collie D, Gregor A, Ebmeier KP, Jarvis G, Lander F, Cull A, Sellar R, Brada M, Thomas C, Elyan S, Hines F, Ashley S, Stenning S, Bernstein JJ, Goldberg WJ, Roelcke U, Von Ammon K, Hausmann O, Radu EW, Kaech D, Leenders KL, Fitzek MM, Aronen JE, Hochberg F, Gruber M, Schmidt E, Rosen B, Flschman A, Pardo P, Afra UMU, Sipos L, Slouik F, Boiardi A, Salmaggi A, Pozzi A, Farinotti L, Fariselli L, Silvani A, Brandes A, Scelzi E, Rigon A, Zampieri P, Pignataro M, Amanzo PD, Amista P, Rotilio A, Fiorentino MV, Thomas R, Brazil L, O'Connor AM, Ashley S, Brada M, Salvati M, Cervoni L, Puzzilli F, Cervoni L, Salvati M, Raguso M, Cruickshank GS, Duckworth R, Rumpling R, Rottuci M, Fariselli L, Boiardi A, Broggi G, Plrint NG, Sabattini E, Manetto V, Gambacorta H, Poggi S, Pileri S, Ferracini R, Grant R, Plev DV, Hopf NJ, Knosp E, Bohl J, Perncczky A, Kiss R, Salmon I, Catnby I, Dewitte O, Brotchi J, Pasteels JL, Camby I, Salmon I, Darro F, Danguy A, Brotchi J, Pasteels JL, Kiss R, Kiu MC, Lai GM, Yang TS, Ng KT, Chen JS, Chang CN, Leung WM, Ho YS, Rychter MD, Klimek A, Liberski PP, Karpinaka A, Krauseneck P, Schöffel V, Müller B, Kreth FW, Faist M, Warnke PC, Ostertag CB, Nielen KMBV, Visscr MC, Lebrun C, Lonjon M, Desjardin T, Michiels JF, Chanalet SLJL, Roche JL, Chatel M, Mastronardi L, Puzzilli F, Osman FJ, Lunardi P, Matsutani M, Ushio Y, Takakura K, Menten J, Hamers H, Ribot J, Dom R, Tcepen H, Müller B, Weidner N, Krauseneck P, Naujocks G, van Roost D, Wiestler OD, Kuncz A, Nieder C, Setzel-Sesterhein M, Niewald M, Schnabel I, O'Neill KS, Kitchen ND, Wilkins PR, Marsh HT, Pierce E, Doshi R, Deane R, Previtali S, Quattrini A, Nemni R, Ducati A, Wrabetz L, Canal N, Punt CJA, Stamatakis L, Giroux B, Rutten E, Quigley MR, Beth Sargent PAC, Flores N, Simon S, Maroon JC, Quigley MR, Beth Sargent PAC, Flores N, Maroon JC, Rocca AA, Gervasoni C, Castagna A, Picozzi P, Giugni E, Rocca AA, Tonnarelli GP, Ducati A, Mangili F, Truci G, Canal N, Giovanelli M, Roelcke U, Von Ammon K, Radu EW, Leenders KL, Sachsenheimer W, Bimmler T, Seiwald M, Eiter HRW, Ortler M, Obwegesser A, Kostron H, Steilen H, Henn W, Moringlane JR, Kolles H, Feiden W, Zang KD, Sleudel WI, Steinbrecher A, Schabet M, Heb C, Bamberg M, Dichgans J, Stragliotto G, Delattre JY, Poisson M, Zampieri P, Brandes A, Rigon A, Tosatto L, D'Amanzo P, Menicucci N, Rotilio A, Mingrino S, Steudel WI, Feld R, Henn W, Zang KD, Maire JP, Caudry M, Guerin J, Celerier D, Salem N, Demeaux H, Fahregat JF, Kusak ME, Bucno A, Albisua J, Jerez P, Sarasa JL, Garefa R, de Campos JM, Kusak ME, de Campos JM, Bueno A, García-Delgado R, Sarasa JL, García-Sola R, Lantsov AA, Shustova TI, Lcnartz D, Wellenreuther R, von Deirnling A, Köning W, Menzel J, Scarpa S, Manna A, Reale MG, Oppido PA, Carapella CM, Frati L, Valery CA, Ichen M, Foncin JP, Soubrane C, Khayat D, Philippon J, Vaz R, Cruz C, Weis S, Protopapa D, März R, Winkler PA, Reulen HJ, Bise K, Beuls E, Berg J, Deinsberger W, Böker DK, Samii M, Caudry M, Darrouzet V, Guérin J, Trouette R, Causse N, Bébéar JP, Parker F, Vallee JN, Carlier R, Zerah M, Lacroix-Jousselin C, Piepmeier JM, Kveton J, Czibulka A, Tigliev GS, Chernov MP, Maslova LN, Valdueza JM, Jänisch W, Bock A, Harms L, Bessell EM, Graus F, Punt J, Firth J, Hope T, Koriech O, Al Deeb S, Al Moutaery K, Yaqub B, Silvani A, Salmaggi A, Pozzi A, Franzini A, Boiardi A, Goldbrunner R, Warmuth-Metz M, Paulus W, Tonn JC, Roosen K, Strik II, Müller B, Markert C, Pflughaupt KW, Krauseneck P, O'Neill BP, Dinapoli RP, Voges J, Sturm V, Deuß U, Traud C, Treuer H, Lehrke R, Kim DG, Müller RP, Alexandrov YS, Moutaery K, Aabed M, Koreich O, Ross GM, Rajan B, Traish D, Ashley S, Ford D, Brada M, Schmeets ILO, Jager JJ, Pannebakker MAG, de Jong JMA, van Lindert E, Knosp E, Kitz K, Blond S, Dubois F, Assaker R, Baranzelli MC, Sleiman M, Pruvo JP, Coche-Dequeant B, Matsutani M, Takakura K, Sano K, PetriČ-Grabnar G, Jereb B, Župančič N, Koršič M, Rainov NG, Burkert W, Ushio Y, Kochi M, Itoyama Y, de Campos JM, Kusak ME, Sarasa JL, García R, Bueno A, Ferrando L, Hoang-Xuan K, Sanson M, Merel P, Delattre JY, Poisson M, Delattre O, Thomas G, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Haritz D, Obersen B, Grochulla F, Gabel D, Haselsberger K, Radner H, Pendl G, Brada M, Laing RW, Warrington AP, Nowak PJCM, Kolkman-Deurloo IKK, Visser AG, Berge HD, Niël CGJH, Levendag PC, Bergström P, Hariz M, Löfroth PO, Bergenheim T, Henriksson R, Blond S, Assaker R, Cortet-rudelli C, Dewailly D, Coche-dequeant B, Castelain B, Dinapoli R, Shaw E, Coffey R, Earle J, Foote R, Schomberg P, Gorman D, Girard N, Courel MN, Delpech B, Haselsberger K, Friehs GM, Schröttner O, Pendl G, Pötter R, hawliczek R, Sperveslage P, Prott FJ, Wachter S, Dieckmann K, Würker M, Herholz K, Pietrzyk U, Voges J, Treuer H, Sturm V, Bauer B, Heiss WD, Jund R, Zimmermann F, Feldmann HJ, Gross MW, Kneschaurek P, Molls M, Lederman G, Lowry J, Wertheim S, Voulsinas L, Fine M, Lederman G, Lowry J, Wertheim S, Fine M, Voutsinas I, Qian G, Rashid H, Lederman G, Lowry J, Wertheim S, Fine M, Voulsinas L, Qian G, Rashid H, Moutaery K, Aabed M, Koreich O, Scerrati M, Montemaggi P, Iacoangeli M, Pompucci A, Roselli R, Trignani R, Rossi GF, Shin K, Mechtler L, West C, Grand W, Shin K, Sibata C, West C, Mechtler L, Grand W, Thomas R, Guerrero D, James N, Ashley S, Gregor A, Brada M, Voges J, Sturm V, Bramer R, Pahlke H, Lehrke R, Treuer H, Banik N, Kim DG, Hövels M, Bernsen HJJA, Rijken PFJW, Van der Sanden BPJ, Hagemeier NEM, Van der Kogel AJ, Koehler PJ, Verbiest H, Jager J, Vecht CJ, Ross GM, McIlwrath A, Brown R, Mottolesb C, Pierre'Kahn A, Croux M, Roche JL, Marchai J, Delhemes P, Tremoulet M, Stilhart B, Chazai J, Caillaud P, Ravon R, Passacha J, Bouffet E, Dirven CMF, Mooy JJA, Molenaar WM, Lewandowicz GM, Grant N, Harkness W, Hayward R, Thomas DGT, Darling JL, Delepine N, Subovici II, Cornille B, Markowska S, Alkallaf JCD, KühI J, Niethammer D, Spaar HJ, Gnekow A, Havers W, Berthold F, Graf N, Lampert F, Maass E, Mertens R, Schöck V, Aguzzi A, Boukhny A, Smirtukov S, Prityko A, Hoiodov B, Geludkova O, Nikanorov A, Levin P, Rothbart D, Balledux J, Criscuolo GR, D'haen B, Van Calenbergh F, Casaer P, Dom R, Menten J, Goffin J, Plets C, Hertel A, Hernaiz P, Seipp C, Siegler K, Baum RP, Maul FD, Schwabe D, Jacobi G, Kornhuber B, Hör G, Menten J, Casaer P, Pilkington GJ, Merzak A, Rooprai HK, Bullock P, van Domburg PHMF, Wesseling P, Thijssen HOM, Wolff JEA, Boos J, Krähling KH, Gressner-Brocks V, Jürgens H, Schlegel J, Scherthan H, Arens N, Stumm G, Kiessling M, Merzak A, Koochekpour S, Pilkington GJ, Reifenberger G. Abstracts. J Neurooncol 1994. [DOI: 10.1007/bf01070874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
Caronti B, Palladini G, Bevilacqua MG, Petrangeli E, Fraioli B, Cantore G, Tamburrano G, Carapella CM, Jaffrain-Rea ML. Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors. Tumour Biol 1993; 14:59-68. [PMID: 8493452 DOI: 10.1159/000217826] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Six human pituitary adenoma cultures, characterized for estrogen and progesterone (Pg) receptors, were treated with 17 beta-estradiol (17 beta-E2), Pg and tamoxifen (TAM) at different concentrations, alone and in combination, for 2, 4 and 8 days. Cell proliferation data showed in most cases a stimulating effect of 17 beta-E2 and an inhibitory effect of Pg on cell growth, which appeared to be correlated with specific receptor expression, but independent of pituitary cell hormone content. A marked inhibitory effect of TAM on cell proliferation was present in all cases, but, on the contrary, was independent of estrogen receptor expression.
Collapse
Affiliation(s)
- B Caronti
- Department of Neurological Sciences, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Jandolo B, Pietrangeli A, Pace A, Carapella CM, Finocchiaro R, Morace E. Brain-stem auditory evoked potentials in supratentorial brain tumors. Electromyogr Clin Neurophysiol 1992; 32:307-9. [PMID: 1623847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A group of 42 adult patients with supratentorial brain tumors were studied with computed tomography (CT or/and NMR) and brain-stem evoked potentials (BAEPs). 12 patients had meningiomas and 30 had malignant tumors (gliomas and metastases). The latencies of wave V and of the interpeak latency I-III, III-V and I-V were evaluated both on the lesion side and the opposite side. In meningiomas mean latencies did not show significant differences from normal, while mean latencies in malignant tumors were significantly prolonged, except for the I-III interpeak latency. The results of this study demonstrate that BAEPs may be altered by supratentorial brain tumors. This examination appears to be useful in the monitoring of these lesions after treatment.
Collapse
Affiliation(s)
- B Jandolo
- Servizio di Neurologia, Istituto Regina Elena, Roma, Italy
| | | | | | | | | | | |
Collapse
|
38
|
Carapella CM, Paggi MG, Calvosa F, Cattani F, Jandolo B, Mastrostefano R, Raus L, Riccio A. Lonidamine in the combined treatment of malignant gliomas. A randomized study. J Neurosurg Sci 1990; 34:261-4. [PMID: 2098504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. A randomized study started in November 1983, to evaluate the efficacy of LND in association with radiotherapy as first line treatment in malignant gliomas, after surgical procedure. LND was also used in association with Lomustine (CCNU) at the moment of documented clinical and neuroradiological recurrence. At the present time 60 patients entered the study, and 47 are evaluable. Present preliminary results are not statistically significant, however indicate that LND tends to prolong the median survival time and the rate of one year survivors.
Collapse
Affiliation(s)
- C M Carapella
- National Institute for Cancer Research, Regina Elena, Roma, Italy
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Occhipinti E, Carapella CM, Calvosa F, Raus L, Riccio A. Surgical treatment of paediatric malignant neuroepithelial brain tumors. J Neurosurg Sci 1990; 34:301-2. [PMID: 2098509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The role of the neurosurgeon in dealing with malignant neuroepithelial brain tumors, both supra- and infratentorial, in paediatric age, is stressed; this because surgery is the main therapy, and also it is mandatory, in order to achieve the pathological diagnosis, essential for planning any kind of complementary treatment. Open surgery versus stereotactic biopsy is considered, with emphasis on brain stem tumors. The treatment of malignant tumor recurrencies is also discussed, and the indications of a second surgical look in patients harboring recurrent medulloblastoma is proposed for discussion, when long disease-free time occur and combined modality treatments are performed.
Collapse
Affiliation(s)
- E Occhipinti
- Division of Neurosurgery, National Institute for Cancer Research Regina Elena, Rome, Italy
| | | | | | | | | |
Collapse
|
40
|
Roselli R, Iacoangeli M, Carapella CM, Scerrati M. The progression in astrocytic tumors. J Neurosurg Sci 1990; 34:199-204. [PMID: 2098497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Progression represents the qualitative tumor evolution during the time. Recently it received great consideration, mainly since the introduction of the neuroradiological imaging (CT and MRI). A series of 224 supratentorial astrocytic tumors of the juvenile and adult age have been analyzed: we found the morphological features of progression in 26% of them. These data introduce, perhaps, the most important information about progression: the "crisis" of the concept that low-grade tumors are stable lesions during the time.
Collapse
Affiliation(s)
- R Roselli
- Istituto di Neurochirurgia, Università Cattolica, Roma, Italy
| | | | | | | |
Collapse
|
41
|
Paggi MG, Fanciulli M, Del Carlo C, Citro G, Carapella CM, Floridi A. The membrane-bound hexokinase as a potential marker for malignancy in human gliomas. J Neurosurg Sci 1990; 34:209-13. [PMID: 2098498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Hexokinase is a key enzyme in carbohydrate metabolism. Its activity has been shown elevated in cells with high mitotic index. In particular, experimental cancer cells, due to their peculiar energy metabolism, display a hexokinase activity proportional to the degree of malignancy. This is the case also for human gliomas in which glucose metabolism, evaluated via positron emission tomography, has been shown to be predictive for patient prognosis. In order to better correlate these findings, specific reagents for tumor hexokinase (a polyclonal antibody and a full-length cDNA probe both specific for murine tumor hexokinase) have been successfully employed to quantitate the protein and its messenger in cultured cell lines; the antibody was also tested in four specimens obtained from human astrocytomas.
Collapse
Affiliation(s)
- M G Paggi
- Regina Elena Institute, Laboratory for Cell Metabolism and Pharmacokinetics, Rome, Italy
| | | | | | | | | | | |
Collapse
|
42
|
Mottolese M, Carapella CM, De Santis M, Mastrostefano R, Raus L, Salzano M, Pericoli N, Riccio A, Natali PG. The role of immunocytochemical assays in the diagnosis of stereotactic biopsies from intracranial tumors. J Neurosurg Sci 1990; 34:223-5. [PMID: 2098500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A selected panel of monoclonal antibodies (MoAbs) directed to distinct tumor associated antigens (TAA) has been tested to define the capability of these reagents to differentiate among metastatic carcinoma, lymphoma and primary brain tumor on cytologic specimens obtained with stereotactic techniques. Results obtained on 50 patients bearing either single or multiple brain lesions demonstrated that immunocytochemical (ICC) methods can distinguish between primary brain tumor and brain metastasis suggesting, in 90% of patients with cryptic primary neoplasia, the site of origin of the tumor.
Collapse
Affiliation(s)
- M Mottolese
- National Institute for Cancer Research, Regina Elena, Roma, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Carapella CM, Paggi MG, Cattani F, Ciottoli GB, Floridi A, Iandolo B, Raus L, Riccio A, Caputo A. The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study. J Neurooncol 1989; 7:103-8. [PMID: 2666593 DOI: 10.1007/bf00149384] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.
Collapse
Affiliation(s)
- C M Carapella
- Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Carapella CM, Mastrostefano R, Raus L, Riccio A. Methodology of stereotactic biopsy. J Neurosurg Sci 1989; 33:5-10. [PMID: 2674358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The great technological improvement in the neurosurgical tools and in the neuroradiological imaging has brought about the diffusion of the stereotactic techniques. They are crucial for the diagnosis and treatment of intracranial expanding lesions of small dimensions or located in sites inaccessible to conventional techniques. The Authors describe the most common systems and methodologies for the stereotactic biopsy. They stress the importance of performing serial explorations which can provide evidence of the heterogeneity of the neoplastic lesion and of the infiltration of the brain adjacent to the tumor.
Collapse
Affiliation(s)
- C M Carapella
- Division of Neurosurgery, Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | |
Collapse
|
45
|
Leonetti C, D'Agnano I, Del Bufalo D, Carapella CM, Zupi G. Human glioma lines as experimental model for biological and chemosensitivity studies. J Neurosurg Sci 1989; 33:39-42. [PMID: 2674355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The use of rodent tumor lines is no longer satisfactory for either biological and chemosensitivity studies because of their well demonstrated difference in behaviour when compared to human tumors. With the employment of human tumor cell lines, both in vitro and in vivo, in nude mice, it is now possible to utilize an extremely more reliable model system able to specifically evaluate many biological features of human tumors as well as their chemosensitivity. Particularly, glioma-derived human tumor lines which grow both in vitro and in nude mice, allowed to assess several parameters able to indicate new therapeutic strategies.
Collapse
Affiliation(s)
- C Leonetti
- Laboratory of Preclinical Chemotherapy, Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | | | |
Collapse
|
46
|
Paggi MG, Carapella CM, Fanciulli M, Del Carlo C, Giorno S, Zupi G, Silvestrini B, Caputo A, Floridi A. Effect of lonidamine on human malignant gliomas: biochemical studies. J Neurooncol 1988; 6:203-9. [PMID: 3225640 DOI: 10.1007/bf00163702] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Lonidamine (LND) has been shown to inhibit tumor aerobic glycolysis. Its effect was evaluated on several human astrocytomas at different degrees of malignancy; a correlation was found between LDN effect on lactate production and tumor malignancy: in grade I and II astrocytomas LND stimulates lactate production, while in grade III, IV and glioblastoma multiforme lactate production is inhibited. In an attempt to explain this different behaviour, hexokinase content and compartmentation was evaluated in astrocytomas from fresh operatory specimens and from cultured cells as well, observing a significative correlation between malignancy, hexokinase activity, percent of mitochondrially-bound hexokinase and LND effect. The results justify from a biochemical point of view the role of LND as a 'non-conventional' agent in multimodality combined treatment for malignant gliomas.
Collapse
Affiliation(s)
- M G Paggi
- Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Pompili A, Jachetti M, Carapella CM, Crecco M, Gaudino G, Isabella F, Mastrostefano R. [Primary empty sella. Clinico-radiologic considerations in 18 cases]. Minerva Med 1985; 76:91-8. [PMID: 4038790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
18 patients with "primary empty sella" were reviewed for this study. In 3 of them the sellar enlargement was discovered occasionally by performing skull radiographs for other reasons. The galattorrhea-dismenorrhea or amenorrhea syndrome and obesity were the most common clinical features. Endocrinological tests were normal in ten patients and abnormal in eight. Slight elevation of serum PRL was the most common record. 12 patients had enlarging of the sella turcica; in 4, only the floor was asymmetric and in 2 the sella was quite normal. In 5 patients C.T. without intra-thecal contrast was sufficient to discover the E.S. In 13 patients we performed C.T. cysternography by injecting in the lumbar subarachnoid space 8-10 ml of Iopamidolo 200. This is an excellent and safe technique to perform C.T. cysternography.
Collapse
|
48
|
Abstract
As part of a multicenter study on Lonidamine, this drug was studied in 16 patients with malignant gliomas. General and neurological examination, electroencephalography, electroneuromyography, and CT scan were repeated at regular intervals. The most common side effects were myalgia, nausea, and vomiting which usually subsided during treatment except in 4 patients. There was an indication of therapeutic activity in 4 out of 16 patients treated with Lonidamine.
Collapse
|
49
|
Carapella CM, Pompei P, Mastrostefano R, Occhipinti E, Rocco A, Falaschi P. Calcified pituitary adenoma associated with severe hyperprolactinemia. Case report. J Neurosurg 1983; 59:871-4. [PMID: 6619941 DOI: 10.3171/jns.1983.59.5.0871] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A patient with a completely calcified chromophobe adenoma is reported. Endocrine evaluation revealed very high prolactin levels. Such extensive calcifications in prolactin-secreting adenomas are extremely rare. The possible pathogenetic mechanisms of this association are discussed.
Collapse
|
50
|
Fontana M, Carapella CM, Caroli F, Riccio A. Spinal meningioma: an unusual radiological and clinical case. Neurosurgery 1982; 11:811-2. [PMID: 7162578 DOI: 10.1227/00006123-198212000-00019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Abstract
The authors report a case of extra-intradural meningioma with an unusual myelographic appearance and a long clinical history. Some interesting radiological and clinical aspects of the lesion and possible pathogenetic mechanisms causing the erosion of the L-2 vertebra are discussed.
Collapse
|